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                                                     INTRODUCTION 
 
            Siddha system or indigenous Tamil medicine is a comprehensive system being in 
practice since time immemorial Tamil land owns a non-detachable tradition of Siddha 
medical science that has surpassed many attacks and invasions both   in land and foreign.   
The origin of Siddha medical science is attributed to the origin of Tamil language.  
However historians believed that the period of documented literature falls from 5
th
 
century B.C to 14
th
 century A.D. from this period there was systematic development of 
the Siddha science, our ancients of our country had a clear knowledge about the 
beneficial effects of medicinal herbs, minerals, and metals arsenic matters upon the 
various diseases that affect the human body. They learned by wide experience and we 
have inherited such valuable wealth of palm scripts left by them.   When a number of 
classical works were produced by several authors they were organized as a documented 
medical Cure system. 
           A great deal of Siddha medicine comes to us from the selfless work of untiring 
souls called Siddhars who preferred obscurity .They are the greatest scientists both 
material and spiritual of ancient period. The Siddhars sought to reveal the deepest truth of   
human physiology and health. These Siddhars teachings were customarily passed on 
orally from teacher to student over decades. Siddha is not only a science of medicine but 
it includes several other disciplines like the rasavatham (alchemy), kayakarpam 
(rejuvenation), yogam, panjapatchisastram,saram,varmam etc. 
         Siddha Medical system enlists 64 kinds of medicine including 32 kinds of internal 
medicine and 32 kinds of external medicines. They have contributed tremendous work on 
raw materials from herbal, mineral, and herbo-mineral, metal and animal origin. 
               The great sage Yugi mentioned in his textYugivaithyachinthamani classified 
vatha diseases into 80 types and kumbavathamis one among them that can becorrelated 
with symptoms of Periarthritis of shoulder joint. . Shoulder pain is the third most 
common musculoskeletal condition that has alife time prevalence of upto 70% and this 
seems to be increasing in incidences .prevalence of frozen shoulderis estimated to be 
2%to5% in general population. People with diabetic mellitus are at greater risk of 
developing periarthritis with a prevalence of 10% to12%.Periarthritis shoulder is defined 
as a clinical syndrome characterized by pain, restriction of both active and passive 
shoulder movements due to cause within the shoulder joint or remote.  The patients have 
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constant shoulder pain with restriction of movements and unable to do the daily routine 
activities. 
The current clinical treatments mainly include administration of non-steroidal 
anti-inflammatory drugs, muscle relaxants, physiotherapy, analgesics, and so on
.
 The 
treatment in other system does not give complete relief. The most optimal treatment has 
not yet been established. The visitation of kumbavaatham increases day by day at 
Ayothidhas Pandithar hospital and constant shoulder pain and restriction of movement are 
affecting the routine life, and this reaction made the me to select this treatment protocol. 
Hence I had selected “Rajaelathy chooranam” (Internal medicine) and 
Nathaichoori ennai (External medicine) along with varmam theraphy for treating the 
disease with minimum cost effective. The selected internal medicine is mentioned in the 
text Kosayae Anuboga Vaithiya Brahmaragayasam 2
nd
 part and external medicine in the 
text Sarabenthra Vaithiya Muraigal-Vatharoga sigitchai, the ingredients of internal drug 
Milagu- Piper nigrum,  Elam - Elattaria cadamomum, Kirambu - Syzygium aromaticum 
have the anti-inflamatory, analgesic and anti-oxidant properties.  
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AIM AND OBJECTIVE 
Primary objective 
 
To evaluate the therapeutic efficacy of Rajaelathy chooranam (Internal) and 
Nathaichoori ennai (External) along with Varmam theraphy in reducing pain and 
restriction of movement in the treatment  of  “Kumbavatham.” 
 
Secondary objective 
 
 To access the predominance of the disease related to age, sex, occupation etc. 
 To correlate the etiology, clinical features, signs and symptoms of Kumbavaatham 
in siddha system with Periarthritis shoulder in Modern science. 
 To evaluate the toxicity of trial drug. 
 To evaluate the biochemical analysis of trial drug. 
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SIDDHA ASPECTS 
 
  Synonym: Kumba vali, Paaggu vatham, Paarisa paagu vaatham. 
  Definition: 
  Kumbavaatham = Kumbam + vaatham                                        
  (Kumbam- upper part of shoulder, Vaatham- derangement of vayu thathu ) 
Kumba vaatham is a clinical condition characterized by pain in shoulder joint 
which radiate to arm with restriction of movement.  
 
“etpyNt Njhs;kPJk; fuj;jpd; fuj;jpd; kPJk; 
eype;jnkj;j thfpNa erTz;lhFk; 
ftpyNt fd;dNkhL eade;jhDk; 
fLj;JNk tpWtpWg;G nkhpTq; fhZk; 
JtpyNt Jbg;ghFq; rpuR jd;dpw; 
Row;wpNa ehgpf;fPo; typAz;lhk; 
mtpyNt mbehf;fpy; mod;W fhZk; 
kyUNk tUFk;g thje;jhNd”. 
                                                                         -Yogivaithiya chinthamani 
 Clinical Pain in shoulder and arm. 
 Muscle weakness in shoulder and arm 
 Burning sensation in eyes and cheeks. 
 Giddiness and twitching over the scalp 
 Pain below the umbilicus. 
 Burning sensation in the tongue 
 
PAAGU VAATHAM 
   “J}Nahh; ghFthjk; ,UNjhspy;; fLg;ghk; 
   MNah ntd;W muw;Wgfy; my;Yk;.P 
- Agathiyar vaithiya chinthamanivenbaa-4000 
 
Pain present in both shoulder joint causing sleep disturbances 
 
PAARISA PAAGU VAATHAM: 
 “J}q;fhky; Neha; nra;Aj; Njhnshd;wp thjkpF 
  ghq;fhFk; ghhPrghF”   
- Agathiyar vaithiya chinthamanivenbaa-4000 
Pain in any one of the shoulder joint with sleep disturbance 
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 The symptoms of Paagu vaatham and Paarisapaagu vaatham can be compared with    
Kumbavatham. 
AETIOLOGY: 
According to text Yugi vaidhya chinthamani 
 Lying in cold floor leads to Kumbavaatham 
According to the text „Pararasasekaram’ 
 Intake of acrid, bitter, pungent containing  foods 
 Excess intake of grains 
 Irregular sleeping pattern 
  Excessive food conception, frequent starvation 
 Sexual indulgence 
 Increased fear, anger, and sadness 
 Over exposure to air. 
 Irregular diet timings will produce Vaatha diseases. 
 
According to the text Sarabenthirar Vaithiya Muraigal- Vaatha Rokha Sikitchai 
 
 Consuming low quantity of food. 
 Sexual indulgence 
 Reduced sleep 
 Doing heavy work 
 Weakness due to sorrow, diseases, worries 
 Control of reflexes like defecation and urination 
 Conversion of undigested food  into toxic substances (Aamam) 
 Trauma 
 Control of hunger 
 Injuries in Uyirnilaigal 
 Falling down from vehicle 
 Doing heavy works 
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Classification of Vaatham: 
 Various siddha texts give different classification of the Vaatha disease as follows 
 
SL. 
NO 
NAME OF SIDDHA TEXT 
TYPES 
1. 
 
Agasthiyar – 2000 
“vz;gJ thjkhF kUtifg;gLj;jpf; fhzpd; 
ez;GW miuf;FNkNy ehw;gJ thjkhFk; 
gzpr;Nruiu;fFf; fPNo gj;J ehd;fhFnkd;W 
tz;LNrh; FoypdhNs thjj;jpd; $WjhNd” 
80 
2. Agasthiyar  Gurunaadi– 235 84 
3. 
Agasthiyar Rathina Churukkam – 500 
“khw;wNk thjNuhfk; tif vz;gj;J ehNy” 
84 
4. Ashataanga Sangiragam 
85 
 
5. 
Bohr Vaidhiyam – 700 
“thr;nrd;w thjk; vz;gJTk; NghFk;” 
80 
6. Jeeva Rakshaamirdham 80 
7. Noi naadal and Noi Mudhal Naadal – Part II 
85 
 
8. Thanvandhiri Vaidhiyam 
80 
 
9. Theraiyar Vaagadam 
81 
 
10. 
Yogi Vaidhiya sindhaamani perunool – 800 
“vd;dNt thjkJ vd;gjhFk;” 
80 
11. Yogai Vaidhiya sindhaamani perunool – 800 84 
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“Mkg;gh thjk; nkz;gj;J ehY 
 mjDila Fzh Fzq;f ylq;;fyhf” 
 
12. 
Rathina surukka naadi  
“ehslh ehw;gj;J ehY E}W 
 eaKlNd ehw;gj;J vl;L Nuhfk; 
ghug;gh thjkJ” 
84 
  
Locations of Vaatham: 
 Below the navel 
     “ehnkd;w thjj;Jf; fpUg;gplNk Nfsha;  
        ehgpf;Ff; fPnod;W etpy yhFk;”   
                 - A+fpKdp 
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As per Yugi muni, Vaatham lies in 
1. Abaanan 
2. Edakali 
3. Kamakodi 
4. Undhiyin keezh 
5. Hip region 
6. Bone  
7. Muscles  
8. Nerve 
9. Joints  
10.  Skin  
11.  Hair follicles and 
12.  Stools 
 
Vaatham in normal state lives in Gastro Intestinal Tract, Bones, Ear, Thigh, Hip and Skin. 
 
Qualities of Vaatham: 
1. Kadinam  -  Roughness 
2. Varatchi  -  Dryness 
3. Elesu  -  Light 
4. Kulirchi  -  Coldness 
5. Asaithal  -  Unstableness 
6. Anuthuvam   -  Subtleness  
Opposite Qualities 
1. Miruthu  -  Softness 
2. Pasumai  -  Unctuous 
3. Paluvu  -  Heaviness 
4. Akkini   -  Hotness 
5. Sthiram  -  Stableness 
6. Katti  -  Solidity 
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Types of Vaatham 
 The Siddha classical texts divide the general principles of Vatham into ten 
subsidiary forms that differ from one another by their location in the body (Anatomical) 
and by their particular functions (Physiological).   
 
They are: 
1. PRAANAN: (Heart Centre) 
    It regulates the respiration and digestion.   It is otherwise called as “Uyirkkaal”  
2. ABAANAN: (Moolaadharam Centre) 
  It moves in the whole Genito - Urinary tract and regulates the defaecation, 
Micturation, menstruation, parturition, ejaculation.  It is otherwise termed as 
„kezhnokkukaal‟ 
3. VIYAANAN (Fore head Centre) 
It helps in the circulation of energy throughout the entire nervous system and the 
movements of various parts of the body. It is also transports nutrients and blood 
throughout the entire body.  It is also known as „Paravukaal‟. 
4. UDHAANAN: (Throat Centre) 
  This corresponds to the pharyngeal plexus in the throat region and controls speech 
and breathing.  It is also responsible for the physiological reflex actions like vomiting, 
hiccup, cough, etc., It is otherwise named as „Melonokkukaal‟ 
5. SAMAANAN: (Navel Centre) 
  This corresponds to the navel region and control digestion. It balances the other 
„Vayus. It is also called “Nadukkaal”. 
6. NAAGAN: (Intellectual air) 
It is responsible for the intelligence of an individual, winking, singing, and pilo 
erection. 
7. KOORMAN: (Visual) 
  It is responsible for yawing, closing of mouth (immovable of lower jaw) winking, 
shedding, of tears, /vision and opening of the eyes. 
8. KIRUGARAN: (Secretory air) 
It is responsible for salivation and nasal secretion.  It helps in digestion and 
meditation.  It produces Cough and sneeze. 
  
10 
 
9. DEVADATHTHAN: (Tiresome air) 
  Laziness is attributed to Devadaththan. Ocular movements & human passions are 
attributed to this Vaatham. It stays either at the anus or at urinary orifice. 
10. DHANAJAYAN: (INTRACRANIAL AIR) 
Dhanajayan functions from the nose & it is responsible for the bloating of the 
body after death and also for the foul smell.  
 
THATHU‟S AND THEIR FUNCTIONS: 
 Vatham  -  Separation/ Movement 
 Pitham  -  Conversion/ Transformation 
 Kabam  -  Cohesion/Liquidity 
 
These three humours Vaatham, Pitham and Kabam circulate in the body in 
different proportions and help in the digestion of food and other general physiological 
functions.  The right proportion of each, in proper combination is responsible for 
maintaining the good health. 
When some of the factors like diet, occupation, seasonal variation etc., disturb 
Vaatham, it loses its control, which may be diminished or exaggerated.  So the two Uyir 
thathus are also disturbed which leads to the genesis of “Vaatha” diseases.  Now the Uyir 
thathu Vaatham can be termed as “Vaatha thodam”  
 
DERANGEMENT OF VAATHAM: 
1. Body ache 
2. Pricking Pain 
3. Tearing Pain 
4. Nerve weakness 
5. Mental distress 
6. Movements 
7. Joints pain 
8.  Traumatic pain 
9. Dislocation of joints  
10.  Weakness of organs 
11.  Paralysis of limbs 
12.  Polydypsia 
13.  Sever pain in calf and thigh muscles 
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14. Bony pricking pain  
15.  Anurea and constipation 
16.  Unable to do flexion and extension of the limbs 
17.  All tastes to be like astringent 
18.  Excess Salivation 
 
SIDDHA PATHOLOGY: 
 When some of the factors like diet, occupation, seasonal variation etc., disturb 
Vaatham, it loses its control, which may be diminished or exaggerated.  So the other two 
Uyir thathus are also disturbed which leads to the genesis of “Vaatha” diseases.  Now the 
Uyir thathu Vaatham can be termed as “Vaatha thodam, this simultaneously leads to 
derangement of Udal thaathukkal which produces the symptoms of disease. 
 
STATUS OF VATHAM AS PER SEASONS: 
As per season, the three Uyir thathus gets altered Physiologically Vaatham will be 
pronounced in the last phase of Muthuvenil (Thannilai valarchi), Karkalam (Vetrunilai 
valarchi) & First phase of Koothir Kalam (Thannilai adaithal) 
    [Ref: Siddha maruthuvanga Churukkam]  
 
FACTORS WHICH ALTER VATHAM: 
 
   “thAtpd; Fzj;Jld; #lDyfpy; 
           thAtpdp lq;fspy; Neha;fSz;L 
     thAtpy; Fsh;r;rpjhd; $blNyh 
    te;jpLk; eypfSk; Ntwplj;Nj 
      thAtpy; mdy;jUk; nea;;g;gike;jhy;  
          thATk; mlq;fpLk; tha;ikapJ 
     thAtpd; gpzpfisg; Nghf;fplNt 
            tFj;jpLk; Kdpnkhop fz;bLNk” 
                  
                              - rpj;j kUe;Jthq;f RUffk; 
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1. When hot foods are taken in a vitiated status of Vaatham, “Vaatham” gets Thannilai 
valarchi. 
2. When cold foods are taken in a vitiated status of Vaatham, “Vaatham” gets Vetrunilai 
valarchi. 
3. And when only oil foods with hot foods are taken in a vitiated status of Vaatham, 
“Vaatham” attains “Thannilai (neutralizes) i.e. in its own state that means healthy 
conditions. 
 
THE FEATURES OF EXAGGERATION OF VAATHAM: 
1. Body weakness and darkness 
2. Liking to eat hot foods 
3. Shivering 
4. Abdominal distension 
5. Constipation 
6. Diminution of immunity 
7. Giddiness 
8. Insomnia 
9. Laziness 
 
THE FEATURES OF DIMINUTION OF VAATHAM: 
1. Body ache 
2. Hoarseness of voice 
3. Loss of memory 
4. Semi consciousness 
5. Difficulty to do any work 
6. Paleness and coolness of body 
7. Heaviness of body 
8. Cough, sleep and abdominal distention 
    [Ref: Siddha Maruthuvanga Churukkam] 
 
Symptoms of deranged Vaatham: 
  The signs and symptoms of Vaatha disease have been given in many siddha 
classical text books as follows  
  
13 
 
1. In Agasthiyar – 2000 
 
“thjj;jpd; FzNknjd;dpy kaf;Fe;jpnaq;Fk; kyh;rptf;Fk; 
 ghjq;Fsph;e;J rUthq;fk;gw;wp elf;FKfq; fLf;FQ; 
rPjj;JlNd tapWGz;zhQ; rphpg;gpj; jJe;njwp – %r;rhk; 
 Nghjj; jz;zPh;jhd; thq;Fk; GfOk; gQ;r FzkhFNk” 
1. Unconsciousness 
2. Tingling pain in the face 
3. Redness of eyes 
4. Dysentery  
5. Excessive thirst  
6. General body pain 
7. Chillness of feet 
 
2. Agasthiyar Naadi: 
 
“nrhy;yNt thj kJ kPwpw;why; 
 Nrhh;tile;j thAtpdhy; Njfnkq;Fk; 
 Nky;y iffhy; mrjp Az;lhFk; 
 NkaKlq;Fk; epkpunthz;zhj; jpkph; cz;lhFk;” 
- mfj;jpah; ehb 
3. Theraiyar Vaagadam: 
“thjtPW md;dkpwq;fhJ fLg;Gz;lhFk; tz;zKz;lhk; 
 NkhJ fl;LNuhfk; RuKz;Nlh kpUkYkh Kwq;fhnjd;Dk; 
 xJ#hpa thjkdyhF eLf;fKz;lhk; nghUs;fsha;j; 
 jPnjdNt euk;gprpj;J re;Jfs;NjhWk; fpLf;Fe;jhNd” 
- Njiuah; thflk; 
1. Loss of appetite 
2. Tingling sensation 
3. Fever 
4. Cough 
5. Sleeplessness 
6. Tremor and  
7. Pain in all the joints 
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NOI KANIPPU VIVADHAM (DIFFERENTIAL DIAGNOSIS) 
Some types of Vaatha diseases may mimic like Kumbavaatham.  Careful and clear 
history taking and examination will reveal the correct diagnosis. 
 
Njhs; thjk; 
“NjhsjpNy tPf;fk; fz;L 
Jlh;;e;jpLk; gplhp fz;Zk; 
ehsJ %d;wpd; NkNy  
ey;yNjhh; fLg;Gk; fhl;Lk;  
MdJ rfpj;jplhJ ghhpy; 
mLj;jpLk; Njhspy; thjk; 
RspJ rpuj;Js; ePh; jhDk; 
#o;;e;jpoy; mZFk; jhNd” 
 
Clinical features of 
 Swelling in shoulder region. 
 After three days unbearable pain sensation in occipital region and eyes. 
 Fluid accumulates in head. 
 
rfdthjk; 
“NfSNk fOj;jpd; fPo; miuf;FNkYk;  
Nfbahd fuk; ,uz;Lk; kpfNtnee;J 
thSNk rhPunky;yhk; fdj;jpUf;Fk; 
thypgUf;F kdk; fz;Z kaf;fkhFk; 
VSNk ,uz;L fz;Zk; vhpr;ry; cz;lhk; 
Vw;wkha; kye;jhWk; ,Wfpf; fhZk; 
NfhSNk nfhl;bdJ Nghy; fLf;Fk; 
rfd tspNehapD}l jPh;f;e;jhNd” 
 
CEGENAVAATHAM 
 Pain in the upper back, which is identical with the cervical spine 
 Radiating pain in both the upper limbs 
 Feeling of heaviness of the body 
 Mental depression 
 Giddiness 
 Burning sensation in the eyes 
 Constipation.  
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Tspf;fPy;thA 
typf;Fj;jy; tPf;fq; fhZk; 
 tha;njhz;il twl;rpfha;r;ry; 
jiytyp khh;J bg;Gj; 
 jhq;nfhzh typtPf; fe;jhd; 
epyTfhw; fZf;F wq;F 
 ePLNjhs; Koq;iff; fhw;fhk; 
kyf;Flw; fl;L Nth;it 
 thjj;jpy; tha;tp jhNk. 
VALI KEEL VAYU 
 Pricking pain and swelling of joints 
 Dryness of mouth and throat 
 Fever  
 Headache 
 Palpation in chest. 
 Intolerable pain of the major joints like knee 
 
PATHIYAM: 
The tastes which increase “Vaatham” are Sour and Astringent. 
 
“GspJth tpQ;fq;fwp ahw;G+hp Fk;thjNk 
xspAth; ifg;Ngwpy; gpj;JrPWk; - fpspnkhopNa 
fhh;g;gpdpg;G tpQ;fQ; rl;bujr; 
Nrug; Gzh; NehaZfhNj” 
 
The tastes which neutralize Vaatham are Sweet, sour and salt. 
  “thj Nkypl;lhy; kJuk; Gspag;G  
   NrjKwr; nra;AQ; rpiwAk; - xjf;Nfs; 
   fhue; Jth; frg;G fhl;LQ; Ritnay;yhk; 
   rhug; ghpfhuQ; rhw;W” 
- Kannusamiam 
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LINE OF TREATMENT 
 Universe and body were made up of five Boothams. Any irregularity in them 
causes diseases. In Siddha system of Medicine, the line of treatment plays an important 
role in the normalization of Pancha boothams. In Siddha system, the treatment is based 
on mukkutram theory.  
Treatment is not only for curing the disease but also for the prevention recurrence 
of the symptoms and rejuvenation of udal kattugal. 
The main goal of the treatment was not only healing the disease but also the 
prevention of disease and rejuvenation of udalkattugal. 
These were as follows: 
1) Neekkam (Treatment) 
2) Niraivu (Restoration) 
3) Kaappu (Prevention) 
 
Neekkam (Treatment) 
 
The deranged Vaatham can be balanced by purgation. Hence the purgation drug 
meganatha mathirai 2 at early morning with warm water was given a day before treatment 
then the Internal and external drugs were given. 
 
Internal drug: 
Raja elathy chooranam- 1gm twice a day with warm water 
 
External drug: 
Nathaichoori Ennai– was given for external application over the affected area. 
 External therapy – Varmam therapy 
 
Niraivu (Restoration) 
 
 The diet should be normalizes the Vaatham   and also strengthen the body. 
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Dietary Regimens: 
According to „Siddha Maruthuvanga Churukkam‟ 
 
¦ºí¸Ø ¿£÷§¸¡‰¼ó §¾ýÁ¢ÇÌ ¿ø¦Äñ¦½ö 
    ¾íÌ¦ÀÕí ¸¡Âó ¾Ø¾¡¨Æ- ±í¦¸íÌõ 
    ÜðÎº¢Ú ÓòÐ¦¿ö §¸¡¾¢ø ¯Øó¾¢¨Å¸û 
    Å¡ðÎÁÉ¢ Äò¨¾ Á¾¢ 
 
1. Senkazhuneer 
2. Costus root 
3. Honey 
4. Pepper 
5. Gingely oil 
6. Asafoetida 
7. Thazhuthaazaai 
8. Castor oil 
9. Black gram 
 
These were the food items for the Vaatha patients. 
 Add: 
Tender vegetables: 
 Avarai (Dolichos lablab) 
 Aththi (Ficus racemosus) 
 Murunkai (Moringa oleifera) 
 Sundai (Solanum torvum) 
 Mullangi (Raphanus sativus) 
 Thoothuvelai (Solanum trilobatum) 
 Pirandai (Cissus quadrangularis) 
 Karunai kizhangu (Colocasia antiquarum)  
 Kathiri (Solanum melongena) 
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Greeens: 
 Sirukeerai (Amaranthus tricolor) 
 Mookkurattai (Boerrhavia diffusa) 
 Puliyaarai (Hibiscus cannabinus) 
 Ponnankanni (Alternanthera sessili) 
 Manali (Gisekia pharanaceoides) 
 Mudakkaruththaan (Cardiospermum halicacabum) 
 
Pulses:  
 Ulunthu (Vigna mungo) 
 Pottukkadalai (fried Cajanus cajan) 
 
Dairy products: 
 Cow‟s milk, buttermilk      
 
AVOID: 
 Tubers except karunai kizhangu (Colocasia antiquorum) 
 Maaporulghal (Carbohydrates) 
 Vaazhai (Musa paradisiaca) 
 Kaaramani (Vigna unguiculata) 
 Verkkadalai (Arachis hypogea) 
 Pattaani (Pisum sativum) 
 Mochai (Lablab purpureus) 
 Kezhvaragu (Eleusine coracana) 
 Kambu (Pennisetum typhoideum) 
 Solum (Sorghum vulgare) 
 Sour, astringent foods 
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Kaappu (Prevention) 
The prevention of diseases were well said in the Siddha system of Medicine as 
mentioned in the text „Theraiyar Pinianugaa Vithi‟ 
 
À¡Öñ§À¡õ ±ñ¦½ö¦ÀÈ¢ý ¦Åó¿£÷ ÌÇ¢ô§À¡õ 
À¸üÒ½§Ã¡õ; À¸üÚÂ¢ø§Å¡õ: À¡§Â¡¾ÃÓ ãò¾ 
²Äï§º÷ ÌÆÄ¢Â§Ã¡ ÊÇ¦ÅÂ¢Öõ Å¢Õõ§À¡õ; 
-Ãñ¼¼ì§¸¡õ; ´ý¨ÃÅ¢§¼¡õ; -¼Ð¨¸Â¢ü ÀÎô§À¡õ. 
 
Varmam 
Varmam is an art as well as a science. As an art it can be employed to attack a 
person to disable him and as a science it helps persons recoup from impact of such 
attacks. Varmam has also some similarities to other martial arts such as Silambam, sword 
fighting, Kalari etc. 
The study of Varmam helps us to know the secrets of nerve centres and the 
disease caused and the appropriate treatment prescribed. 
Hundreds of nerve-centres of the human body lie dormant with bones, nerves, veins, 
muscles, joints and inner organs and are found either deep or at the surfaces of the body. 
Vital life centres are dominant on bones and joints; medium life centres on nerves; 
striking life centre on veins. Inner life centres on muscles, and chronic life centres on 
blood clots formed due to impacts on the body. 
 Varmam can be defined as the flow of life force in relationship with breathing. 
 “¦ºôÒÚ ¾¨º¸¦ÇýÒ º¢Ú ¦ÀÕ ¿ÃõÒºóÐ 
 ¾ôÒÚ ¿¡ÊÂ¡Úõ ¾íÌÁ¢¼õ ÅýÁÁ¡§Á.” 
            - Varma Vidhi 
 
 The points where life force resides and flows in the human body are known as 
varmam. It also means the points where breathing energy resides in the body. 
 
  “Å¡º¢ ¾ðÎõ ¾Ä¦ÁøÄ¡õ Å÷Áõ.”                         
        - Varma Odivu Murivu Sara Soothiram-1200 
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 Varmam therapy is a systematic study of vital points (Varmam) on human body 
and also on animal bodies. 
 
      “¯ûÇÀÊ áü¦ÈðÎ ¾Äõ º¡Å¡Ìõ 
         ¯½÷Å¡¸¢ «ò¾Äí¸û ¯Â¢Õ Á¡Ìõ  
      ¸ûÇÓüÈ «ò¾Äí¸û À¢½¢Ô Á¡Ìõ  
         ¸Çí¸ÁüÈ¡ø «ò¾Äí¸û Í¸§Á ¸¡Ïõ  
      ¯ûÙ½÷Å¡ö «ò¾Äí¸û Å¡º¢ §ÂüÈ 
         ¯üÈ¾¢É¡ø «ò¾Äí¸û ¯Ú¾¢ §ºÕõ  
      ÒûÇÊ§À¡ø «ò¾Äí¸û ¸ñ¼ Å÷¸û 
         Ò¸Ä¡÷¸û ±ø§Ä¡Õõ ÒÅ¢Â¢Ûû §Ç¡÷ì§¸."  
-Varma Odivu Murivu Sara Soothiram-1200   
 
 It is also called the art of killing and the art of healing. Right or wrong vibration 
of the vital points will either promote or impair health. Its aim is to produce healthy and 
stable individuals. 
 
Classification of Varmam:  
 
 There are 108 Varmam or Varma points in our body.  
 
1. According to the text Varma Odivu Murivu Soothiram, 
 
1. Padu Varmam        - 12 
2. Thodu Varmam      - 96 
 
 Injury or any hit in the Paduvarmam points may lead to severe deformities or even 
death. The Thodu Varmam points are mostly used in therapeutic purposes. 
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2. According to the text Varma Kannaadi 
  Human body is divided into five divisions, they are: 
 
S.No Area Number of points 
1  From top of  the head to neck 25 
2  From neck to navel point 45 
3  From navel point to anus 9 
4  Both hands 14 
5  Both legs 15 
Total 108 
 
4. According to the text Varma Soothiram, 
 
 Vaatha Varmam      -  64 
 Pitha Varmam     -  24 
 Kaba varmam        -  06 
 Ull Varmam            -  06 
 Thattu Varmam     -  08 
                   Total             - 108 
 
The main causes for impact to nerve centre (Varmam) 
 
      “§¸ÇôÀ¡ ¾ÊÂÊ¸û ÀÎ¾ Ä¡Öõ 
         ¦¸ÊÂ¡É ±È¢Å¢¨º¸û ¦¸¡ûÇ Ä¡Öõ 
       Å¡ÇôÀ¡ ¸ð¨¼ÌüÈ¢ ¾ð¼ Ä¡Öõ  
         Á¡üÈ¡É¢ý ¨¸ôÀ¢Ê¸û ÀÎ¾Ä¡Öõ  
       §ÅÇôÀ¡ ¬¸º¡ Á¾¢§Ä ¿¢ýÚ 
         ¦ÁöÁÈóÐ ¨¸ÁÈóÐ Å¢Ø¾ Ä¡Öõ 
       ¾¡ÇôÀ¡ ÀüÀÄÅ¡õ Å¢¾ò¾¢ É¡§Ä 
         ºí¨¸Â¢øÄ¡ì ¸¡ÄÁÐ º¡Õó ¾¡§É.  
-Odivu Murivu Saari-1200 
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 Hit sustained by a thick and rough stick.  
 Stone thrown at a high speed from a sling.  
 Fall from a tree or height. 
 Fall while running. 
 By leaping. 
 By fainting     
 
 Varma Kalai is said to link up the material body with the spiritual „life‟ or Soul, 
through the mediums of panchabhootham activating the movement of “life” within the 
body carried through the ten vayus. This is the fundamental principle of Yogam and 
Samadhi. 
 A human body requires thasavaayus (10 vaayus) namely, Praanan, Abaanan, 
Udaanan,Viyaanan, Samaanan, Naagan, Koorman, Kirukaran, Devadatthan and 
Dananjayan,for its proper functioning each Vaayu has its own function to keep the body 
healthy and disease free. 
 
BHUJA VARMAM 
 Synonyms 
Poruthu varmam 
Kaiporuthu varmam 
Kaipuja poruthu varmam 
Cheppu varmam 
 
G[ th;kk; 
MFNk G[th;k jyj;ijf; NfS 
 Mdifg; nghUj;jpd; jyk jhFk; 
NghFNk ,j;jyj;jpy; fhaq; nfhz;lhy; 
 nghUj;Jtpl;L vy;Yjhd; tpyfpg; NghFk; 
NtFNk ifajid cau nthl;lhJ 
 tPf;fkhk; Njfnky;yhk; tpah;j;J jsUk; 
Location 
Bhuja varmam rests at the tip of the collar bones on either side. Each upper arm 
has a Bhuja varmam. 
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Features 
 The victim of this disorder will not be able to lift the hands freely. 
 The areas will become numb and swelling will set in. 
 The patient will not have a wink of sleep and become faint. 
 Sleep will be disturbed. 
 
Method of treatment: 
Bring the patient back to consciousness. Give massage on the opposite side of the 
affected life centre. Also rub the back and side ribs. 
 
Benefits 
Used in the disease of shoulder joint and other Vaatha diseases 
 
KAVALI VARMAM 
Synonyms 
Kavali kaalam   
kavali adangal   
 channi adangal varmam.  
“NghlNt jPh;e;JtpLk; ,d;D nkhd;W 
  Gfohd ftspjdpy; ftsp th;kk; 
     ehlNt ,j;jyj;jpy; Kwpe;J Nghdhy; 
  ehopifjhd; njhz;Z}wpy; kuz khthh; 
NjlNt ,J fle;jhy; njhz;Z}whk; ehs; 
  jpz;zkha; khpj;jpLthd; ,ay;g jhf” 
 
Location: 
Kavali varmam is located in the webs between the fingers on both hands. In 
appearance this place looks like the letter „v‟. This formation is known as Kavali. The 
Kavali varmam resides in the depressions between the fingers. 
 
Benefits 
It is used in the treatment of diseases in upper limb. 
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ULLANKAIVELLAI VARMAM 
Synonyms: 
Vellai Varmam                 - Varma Kannadi-500 
Adi kuzhi                         - Varma Vidhi   
Munnoli Varmam            - Varma Soothiram Panjikarana Pinnal 
Karunasakkira kaalam     - Varma Aani 
Kunju pichathi kaalam     - Varma Vilakkam  
 
Location: 
      “¸£÷ò¾¢Â¡õ À¡¾Á¾¢ø ¦Åû¨Ç Å÷Áõ.” 
  - Varma Odivu Murivu Sara Soothiram -1200 
    “ÝðºÁ¼¡ ¦Åû¨ÇÂ¾¢ø «¼í¸ø Å÷Áõ.”        
           - Varma Soothiram- 101 
    “À¨¼ÓÈ¢ò¾¡ý Å÷ÁòÐìÌ þÃñÎ Å¢ÃÖìÌì ¸£§Æ ¯ûÇí¸¡ø Å÷Áõ .....                       
                 -Varma Noolalavu Nool 
 “«ÅÉ¢¾É¢ø ¯ûÇí¸¡ø ¦Åû¨Ç Å÷Áõ.”          
           - Varma Peerangi-100 
“«¸Á¡É ¯ûÇõ ¸¡ø ¦Åû¨Ç Å÷Áõ.”           
                - Adi Varma Sootcham-500 
 
 In the centre of the plantar region 
Benefits 
It cures the diseases in palm, hyperhidrosis in palms and the Vaatha diseases 
affecting the joints. 
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MORDEN ASPECT 
 
ANATOMY OF SHOULDER JOINT: 
The shoulder joint is the proximal joint of the upper extremity and is the most 
mobile of all joints in the human body. The shoulder is the region of upper limb attached 
to the trunk. The bone frame work of the shoulder consists of the clavicle, scapula and 
proximal end of humerus.   
 
 
 
 
 
 
 
 
 
JOINTS OF SHOULDER JOINT: 
There are three joints in the shoulder complex namely 
Glenohumeral joint  
Sternoclavicular joint 
Acromio clavicular joint 
 
Glenohumeral joint: 
The main joint is the glenohumeral joint.  It is a multiaxial ball and socket joint 
and it is the most mobile joint in the body. The head of the humerus is called the ball and 
the glenoid fossa of the scapula is called the socket. The glenoid cavity depth is increased 
by a rim of fibrocartilage that surrounds it. The rim of fibrocartilage is the glenoid 
labrum. Superiorly this larum is continuous with the tendon of long head of biceps  
brachii muscle, which attaches to the supraglenoid tubercle and passes through the 
articular cavity superior to the head of the humerus. The synovial membrane attaches to 
the margins of articular surfaces and lines the fiberous membrane of joint capsule. 
Synovial membrane is loose inferiorly. This redundant region of synovial membrane and 
related fibrous membrane accommodates abduction of the arm. 
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The joint stability is provided by rotator cuff muscles, the long head of biceps 
brachii muscle, related bony processes, and extracapsular ligament. 
 
Sternoclavicular joint:  
The sternoclavicular joint is a sole connection between the axial skeleton and 
upper extremity. It connects the inner part of the clavicle to the sternum. It allows 30-60 
of upward elevation, 35 of anteroposterior movement and 45-50 of rotation about the long 
axis of the clavicle. 
 
Acromioclavicular joint:  
This joint connects the outer part of clavicle to a projection at the top of the 
shoulder blade called the acromion process. It is the only articulation between clavicle 
and scapula little motion exists in this joint. This joint is an encapsulated diarthrodial joint 
held together by its joint capsule and coracoacromial ligaments (trapezoid and conoid 
ligaments) 
 
Rotator cuff: 
The supra spinatus, infraspinatus, teres minor and subscapularis muscle comprise 
the rotator cuff. The muscles and tendons of the rotator cuff form a sleeve around the 
anterior superior and posterior humeral head and glenoid cavity of the shoulder 
compressing the glenohumeral joint. 
 
MUSCLES OF SHOULDER JOINT   
The most superficial muscles of shoulder are trapezius and deltoid together they 
provide characteristic contour of the shoulder 
Deep to the trapezius the scapula is attached with vertebral column by three muscles- the 
levatorscapulae, rhomboid minor and rhomboid major. 
 
1. DELTOID: 
It is large and triangular in shape, with its base attached with the scapula and clavicle 
and its apex attached with humerus. 
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Origin 
Inferior edge of the crest of spine of the scapula, lateral margin of the acromian, 
anterior border of lateral one- third of the clavicle. 
 
Insertion  
Deltoid tuberosity of humerus. 
 
Innervation  
Axillary nerves (c5,c6) 
Functions  
 abductor of the arm 
 Clavicular fibres assist in flexing the arm  
 Posterior fibres assist in Major extension of  the arm 
 
2. TRAPEZIUS  
The muscle has an extensive origin from the axial skeleton. Together the left and 
the right trapezius muscle form a diamond or tapezoid shape. 
Origin 
Superior nuchal line, external occipital protruberance, medial margin of 
ligamentum  nuchae, spinous process of  C7 to T12  and related supraspinous ligaments. 
Insertion  
Superior edge of the crust of the spine of the scapula, acromian, posterior border 
or 0f lateral one-third 0f the clavicle. 
Innervation  
Motor spinal part of accessory nerve  
Anterior rami of C3 and C4 
Functions 
 Powerful elevation of scapula. 
 Rotates the scapula during abduction of humerus above horizontal. 
 Middle fibers retracts scapula. 
 Lower fibers depresses scapula. 
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3. LEVATOR SCAPULAE 
It elevates the scapula 
Origin 
Transverse processes of C1 and C2 vertebrae and posterior tubercles of  transverse 
processes of  C3and C5 vertibrae. 
Insertion  
Posterior surface of medial border of scapula from superior angle to root of spine 
of scapula. 
Innervation  
Branches directly from anterior rami of C3 and C4 spinal nerves and by branches 
(C5) from the dorsal scapular nerve. 
Function 
Elevates the scapula. 
4. RHOMBOID MINOR  
Origin 
Posterior surface of ligamentum nuchae and spinous process of C7 and T1 
vertibrae. 
Insertion  
Posterior surface of medial border of scapula at the root of spine of scapula. 
Innervation  
Dorsal scapular nerve (C4, C5) 
Function 
Elevates and retracts the scapula. 
5. RHOMBOID MAJOR  
Origin 
Spinous processes of T2-T5 vertibrae and innervating supraspinous ligaments. 
Insertion  
Posterior surface of medial border of scapula from the root of the spine of scapula 
to the inferior angle  
Innervation  
Dorsal scapular nerve (C4, C5) 
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Function  
Elevates and retracts the scapula. 
 
SUPRASPINATUS: 
Origin:  
Medial two - thirds of the supraspinous fossa of the scapula and the deep facia that 
covers the muscle. 
Insertion: 
 Most superior facet on the greater tubercle of the humerus 
Innervation: 
 Suprascapular nerve (C5,C6) 
Function: 
Rotator cuff muscle;  initiation of abduction of arm to 15
0
 at glenohumeral joint. 
 
INFRASPINATUS: 
Origin : 
Medial two thirds of infraspinous fossa of the scapula and the deep facia that 
covers the Insertion: 
Middle facet on posterior surface of the greater tubercle of the humerus. 
Innervations: 
 Suprascapular nerve (C5,C6) 
Funtion: 
 Rotator cuff muscle; lateral rotation of the arm at the glenohumeral joint 
 
TERES MINOR: 
Origin:  
Upper two thirds of a flattened strip of bone on the posterior surface of the scapula 
immediately adjacent to the lateral border of the scapula. 
Insertion:   
Inferior facet on the posterior surface of the greater tubercle of the humerus. 
Innervations:  
Axillary nerve (C5,C6) 
Function : 
Rotator cuff muscle; lateral rotation of arm at the glenohumeral joint. 
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TERES MAJOR: 
Origin: 
Elongate oval area on the posterior surface of the inferior angle of the scapula. 
Insertion: 
Medial lip of the intertubercular sulcus on the anterior surface of the humerus. 
Innervation: 
Infrior subscapular nerve (C5, C6, C7) 
Function: 
Medial rotation and extention of the arm at the glenohumeral joint. 
 
LONG HEAD OF TRICEPS BRACHII: 
 Origin; 
Infraglenoid tubercle on scapula 
Insertion: 
Common tendon of insertion with medial and lateralheads on the olecranon 
process of ulna 
Innervations: 
Radial nerve (C6, C7, C8) 
Function: 
Extension of the forearm at the elbow joint; accessory adductor and extensor of 
the arm at the glenohumeral joint. 
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LIGAMENTS OF SHOULDER JOINT 
 
 
 
 
 
 
 
 
 
 
Ligaments of the Acromioclavicular joint: 
 Capsular ligament 
 Superior and inferior acromioclavicular ligament 
 Articular disc 
 Coracoclavicular ligament (trapezoid and conoid ligament) 
 
Ligaments of sternoclavicular joints 
 Capsular ligament 
 Anterior and posterior sternoclavicular ligament 
 Inter and costoclavicular ligament 
 Articular disc 
 
Ligaments of glenohumeral joint 
 Capsular ligament 
 Coraco humeral ligament 
 Glenohumeral ligament 
 Transverse humeral ligament 
 Glenoid of humerus 
 
BURSAE: 
Shoulder bursae refers to sacs surrounding the shoulder joint that are filled with 
synovial fluids. As with bursae in general, they facilitate movement and reduces friction 
at tendon-tendon and tendon-bone interfaces. 
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VASCULAR SUPPLY: 
Acromioclavicular joint: 
It receives its arterial supply from the suprascapular and thoracoacromial arteries. 
Sternoclavicular joint  
 It receives blood supply from inter thoracic and suprascapular arteries. 
Glenohumeral joint 
 Supplied by branches from anterior and posterior circumflex humeral 
suprascapular and circumflex scapular vessels. 
 
DYNAMIC PHYSIOLOGY OF SHOULDER JOINT 
Joints within the shoulder joint allow movements in three planes in space and also 
motion in combination of three planes. 
 Flexion and extension in sagittal plane. 
 Abduction and adduction in the frontal plane. 
 Flexion and extension in horizontal plane while the arm is abducted to 90º 
 Axial rotation, which is the result of movements performed relatively to any two 
of three axes  
 Circumduction which combines movements of all the three axes, its amplitude 
being defined as the code of circumduction. 
 
Range of motion  
Movements of flexion and extension performed in the sagittal plane normally 
range from 180
º
 of flexion to 45
º
 from 30
º 
of adduction to 180
º 
of abduction. 
Motions of upper limb in horizontal plane take place about a vertical axis and 
range from an angle of 30
º
 posterior to the vertical plane of the body to an angle of 140
º 
anterior to this plane. The axial rotation of the arm normally measures from 80
º
 of 
external rotation to 90
º
 of internal rotation. Movements that may be required of the 
shoulder in activities of daily living are complex. 
 
PERIARTHRITIS SHOULDER 
 E. Cod man coined the term “Frozen shoulder” in 1934 and described it as a 
condition difficult to define, difficult to treat and difficult to explain from the point of 
pathology. 
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Earlier S Duplay used the term “Periarthritis Scapulo – humerale” to describe the 
condition in 1872. 
Later J Neviaser used the term “Adhesive capsulitis” in 1945 reflecting the 
findings at surgery and postmortem. 
 
Definition 
 It is defined as a clinical syndrome characterized by painful restriction of both 
active and passive shoulder movements due to causes within the shoulder joint or remote 
(other parts of the body)  It is usually unilateral. Both shoulders may be affected in about 
10 to20% of cases (mainly Diabetic mellitus)
 
 
Epidemiology 
Frozen shoulder syndrome usually affects patient aged 40-60 years. The incidence 
is not precisely known however it is estimated that 2%to 5% of general population 
develops the disease over their life time. Men tend to be affected less frequently than 
women, and there is no predilection for race .In general bilateral shoulder involvement is 
rarely simultaneous and instead occurs sequentially. 
 
Pathophysiology 
Immune, inflammatory and fibrotic changes appear to be involved in the 
pathophysiology of frozen shoulder. The current hypothesis posits inflammation in the 
joint capsule followed by development of adhesions and fibrosis of the synovial lining. 
Thickening and contraction of the glenohumeral joint capsule and formation of 
collagenous tissue surrounding the joint reduces joint volume. 
Matrix metalloproteinase are involved in the constriction of extra cellular matrix 
and in various cytokines that control collagen deposition. The drugs that inhibit matrix 
metalloprotiens can induce conditions similar to frozen shoulder and duputryen disease 
Following the synovial inflammatory process, a high number of fibroblast and 
myofibroblast suggest a fibrotic process in the capsule. The condition is thought to result 
from progressive fibrosis and eventual contracture of the capsule of the gleno humeral 
joint, which causes pain and stiffness.   
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CAUSES 
Primary: Here the exact cause is not known and it could be idiopathic. 
Secondary: according to Lumberg, the secondary causes are 
 Shoulder causes  
 non-shoulder causes 
 
Shoulder causes: problems directly related to shoulder joint which can gives rise 
to frozen shoulder are poor posture can cause shortening of the ligaments around the 
shoulder joint tendonitis of rotator cuff, bicipital tendinitis, fractures, and dislocations 
around the shoulder etc.  
Non shoulder causes: problems not related to shoulder joint like diabetes, cardio 
vascular diseases with referred pain to the shoulder, which keeps the joint immobile, 
reflex sympathetic dystrophy, frozen hand shoulder syndrome, a complication of colles 
fracture, can all read to frozen shoulder.  The reason could be prolonger immobilization 
of the shoulder joint due to referred pain, etc. 
 
CLINICAL FEATURES 
 The patient complains of severe pain in the shoulder and upper arm of 
gradual and spontaneous onset.  
 The patient demonstrates a capsular pattern of movement restriction.(i.e 
external rotation  > abduction >internal rotation ) 
 Pain is noted at the end stage of stretch. 
 Patient is unable to do routine daily activities like combing the hair, 
Women wearing the button of their blouse, doing overhead activities. 
 Pain is often severe to disturb the sleep.  
 
STAGES OF PERI ARTHRITIS: 
Stage 1 (Stage of pain ):  
Patient complains of acute pain, decreased movements, external rotation gratest 
followed by loss of abduction and then forward flexion. Internal rotation is least affected. 
This stage lasts for 10-36 weeks. 
Stage 2 (stage of stiffness): 
In this stage, pain gradually decreases and the patient complains of stiff shoulder. 
slight movements are present. This lasts for 4-12 months. 
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Stage3 (stage of recovery): 
Patient will have no pain and movements would have recovered but will never be 
regained to normal. It lasts for 6 months to 2 years.  
 
TREATMENT 
Conservative  
Stage 1:  
Anti- inflammatory drugs 
Intra-articular steroids only for transient relief of pain only 
Stage 2: 
Both active and passive exercises are gradually begun followed by Physiotherapy, 
ultrasound, heat and shoulder wheel exercises. 
Shoulder manipulation under general anaesthesia. 
Stage 3: 
Active and passive exercises, physiotherapy consisting of ultrasound etc are 
continued.   
Surgery 
Arthroscopic distension (Bruisement technique) 
Arthroscopic release 
 
DIFFERENTIAL DIAGNOSIS 
Cervical spondylosis: 
 Cervical spondylosis, also known as cervical osteoarthritis or neck arthritis, is a 
common, age-related condition that affects the joints and discs in your neck. It develops 
from wear and tear of the cartilage and bones found in your cervical spine, which is in 
your neck. While it‟s largely due to age, it can be caused by other factors as well. 
 
Impingement syndrome: 
Shoulder impingement can be a painful condition that may cause a variety of 
medical issues. Patients may exercise pain in their shoulder, behind their back, and in 
their arms if they develop this condition. If a patient has a complete rotator cuff tear, then 
he may also experience weakness in the affected shoulder and arm. 
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Osteoarthritis of Acromioclavicular joints:  
In its early stages, AC joint osteoarthritis usually causes pain and tenderness in the 
front of the shoulder around the joint. The pain is often worse when the arm is brought 
across the chest, since this motion compresses the joint. The pain is vague and may 
spread to include the shoulder, the front of the chest, and the neck. If the joint has been 
injured in the past, there may be a bigger bump over the joint on the affected shoulder 
than on the unaffected shoulder. The joint may also click or snap as it moves. 
 
Prevention of Periarthritis shoulder: 
“Prevention is better than cure”. Anything you can do to prevent an injury from 
occurring is worth. Stretching and strengthening exercises are best defence against it. 
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INTERNAL MEDICINE 
ELAM 
Botanical name       :  Elettaria cardamomum 
English name             :  Cardamom seeds 
Family   :  Zingiberaceae 
 
Organoleptic character: 
 
Taste                     :  Acrid 
Potency                :  Hot 
Division                : Acrid 
 
General properties: 
 
 njhz;il fhy;fTs; jhYFjq;fspy; 
  Njhd;Wk; Nehtjprhuk;gd-; Nkfj;jhy; 
 cz;ilNghy;vOq; fl;bfphpr;rhuk; 
  coiythe;jprpye;jptp~Q;Ruk; 
 gz;ilntf;iftpjhfNeha; fhrKk; 
  ghOQ; Nrhkg;  gpzptpe;Jel;lKk; 
 Mz;ilaPistd; gpj;jk; ,itf;nfy;yhk; 
  My khq;fko; VykUe;jNj 
Action:  
 Stimulant 
 Carminative 
 Stomachic 
 Antispasmodic 
 Tonic    
 
Chemical constituents: 
                        Alpha terpinyl acetate, Linalyl acetate, Limonen, Linalorl, Cineole, 
citronellol, nerol, transnerolidol 
 
CHUKKU 
 
Botanical name  :  Zingiber officinale 
English name    :  Dried ginger 
Family     :  Zingiberaceae 
 
38 
 
Organoleptic character: 
Taste  : Acrid 
Potency : Hot 
Division : Acrid 
 
General properties: 
 
 சூல஬நந்தம் ந஥ஞ்நெரிப்பு ததோடதநப் ஧ம்நமல஬ 
 ப௄஬ம் இலபப்஧ிருநல் ப௄க்கு஥ீர் – யோ஬க஧ 
 ததோடநதி ெோபந் நதோடர்யோத குன்ந஥ீர்த் 
 ததோடம்ஆ நம்த஧ோக்குஞ் சுக்கு.  
                            -அகத்தினர் குணயோகடம் 
Action: 
 Stimulant 
 Stomachic 
 carminative 
 
Chemical constituents: 
Gingerin, Phellandrane, High flavonoid contents, polyphenols, tannin, isovanilin, 
adenine. 
KOOGAINEERU 
Botanical name  :  Maranta arundinacea 
English name   :  Arrow root 
Family     :  Marantaceae 
 
Organoleptic character: 
 
Taste   : Sweet 
Potency             : Hot 
Division  : Sweet 
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General properties: 
 
 தந஦ினிடும் யோய்க்கு நிருதுயோம் ஆக்கிப௅ண்ணத் 
 தோ஦ிருநல் நயப்஧திக தோகநிலய – ஏ஦ிருக்கும் 
 அம்த஧ ஫ி஭ங்கிமங்கி தினோயர்க்கு நோநணப்பூங்  
 நகோம்த஧ கூலகக்கிமங்லகக் கூறு.  
                  -அகத்தினர் குணயோகடம் 
Action: 
 Refrigerant 
 Demulcent 
 Nutrient 
 
THALISAPATHIRI 
 
 Botanical Name : Taxus buccata 
 English Name : Flaurtiacalaphracta 
 Family  : Taxaceae 
 
Organoleptic Character 
 
Taste  : Acrid 
Potency : Hot 
Division : Acrid 
 
ந஧ோது குணம்: 
  ஥ோெி க஭ப்஧ிணிகள் ஥ோட்஧ட்ட – கோெஞ்சு 
  யோெம் அருெி ய஦நங்கோல் – யெீியரு 
  தநகநந்தம் அத்திசுபம் யிட்தடகுந் தோ஭ிெத்தோல் 
  ஆகுஞ் சுகப்஧ிபெ யம்.  
                                               -அகத்தினர் குணயோகடம் 
Actions: 
 Carminative 
 Stomachic 
 Expectorant 
 Tonic 
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SIRUNAAGAPOO 
 
 Botanical name : Mesua nagassarium 
English name  : Ceylon lorn wood 
Family    : Calophyllaceae 
 
Organoleptic character: 
 
Taste                        : Bitter, astringent 
Potency                 :  coolent 
Division                : Acrid 
 
General characters; 
 
rpWehfg; G+tpdJnra;ifjidr; nrhy;Nthk; 
 FwpahFk; Nkfj;ijf; nfhy;Yk; - newptpl;Lj; 
 jPjha;r; nry;thAite; jPh;f;FkpFkw;Nghf;Fk 
 Nfhjha;!,ijawpe;Jnfhs  
 
Action:   
 Astringent 
 Carminative 
 Anti- inflammatory 
 Anti pyretic 
MILAGU 
 Botanical Name : Piper nigrum 
 English Name : Black pepper 
 Family  : Piperaceae 
 
Organoleptic Character 
 Taste  : Bitter, Acrid 
 Potency : Hot 
 Division : Acrid 
 
ந஧ோது குணம்: 
 “ தீனோகி நனங்கும் திரிப௅நலத னோயத்து 
தநோனோந ந஬ப்஧டிப௅ ப௃ண்டோக்கோற்- ஧ோனோது 
த஧ோந்திநிர்யோ தங்கிபந்தி புண்ணரீும் நண்ணயர்க்கும் 
கோந்திநநய்யோ தச்ெலுப்ல஧க் கோய்” 
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Chemical Constituents: 
 A volatile alkaloid Piperine or Pipirine 5-9%, Piperidine or Piperidin 5%, 
Abalsamic volatile essential 1-2%, fat7%.Mesocarp contains chavicin, a balsamic 
volatile oil, starch, gum, Piperrettine, Piperanine, PipericideSarmentine, Eugenol. 
Ref: Indian Herbal Pharmacopoeia, P – 321. 
Actions: 
 Carminative 
 Pungent 
 Antiperiodic 
 Analgesic 
 Anti- inflammatory 
 Antioxidant 
 Cyclo oxygenase inhibitory activity 
Ref: Indian Herbal Pharmacopoeia, P – 324 Database, Vol. – 190. 
KIRAMBU 
Botanical name : Syzygium aromaticum 
English name        : Cloves, Clove tree 
Family                       : Myrtaceae 
 
Organoleptic character 
 
Taste   : Acrid 
Potency  : Hot 
Divistion  : Acrid 
 
General properties: 
 ஧ித்த நனக்கம் த஧திநனோடு யோந்திப௅ம்த஧ோம் 
 சுத்தயிபத்தக் கடுப்புந் ததோன்றுதநோ – நநத்த 
 இ஬யங்கங் நகோண்டயருக்தகற் சுகநோகும்  
 ந஬நங்தக கட்டுநந஦ யோழ்த்து.  
- அகத்தினர் குணயோகடம். 
Chemical constituents:  
Essential oils mainly contain euginol, euginyl acetate, β-caryophiline. 
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Action: 
 Antispasmodic 
 Carminative 
 Stomachic 
 
SUGAR 
Botanical name : Saccharum officinarum. Linn 
English name        : Sugar cane 
Family                       : Poaceae 
 
Organoleptic character 
Taste   : Sweet 
Potency  : Coolent 
Division  : Sweet 
 
General properties: 
 
 ெீ஦ிச் ெர்க்கலபக்குத் தீபோத யன்சுபப௃ங் 
 கூ஦ிக்கும் யோதத்தின் கூட்டு஫வும் – ஏ஦ிருக்கும் 
 யோந்தி நனோடுகிருநி நோ஫ோத யிக்கலுதந  
 த஧ோந்திலெலன யிட்டுப் புபண்டு.  
- அகத்தினர் குணயோகடம். 
Action: 
 Antiseptic 
 Demulcent 
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EXTERNAL MEDICINES 
NATHAI CHOORI 
Botanical name  :  Spermacoce hispida 
English name       :  shaggy button weed 
Family                      :   Rubiaceae 
 
Organoleptic character: 
 
Taste                : sweet, astringent 
Potency  : Coolent 
Division  : sweet   
 
Action:     
 Alterative 
 Tonic 
 Anti- inflammatory 
 Hypolipidaemic 
      Alkaloids: 
 Borreline  
 Beta-sitostero 
 Ursolic acid 
 Iso-rhamnesin 
VASAMBU 
Botanical name: Acorus calamus 
English name : Sweet flag 
Family : Araceae 
 
Organonoleptic character: 
Taste  : Acrid 
Potency : Hot 
Division : Acrid 
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General properties: 
  ஧ோம்஧ோதி ஥ஞ்ெோற் புதப்புண் ய஬ியிட஧ோகங் குன்நம் 
  சூம்஧ோ ரிபத்த஧ித் தம்ப௃க ஥ோற்஫ம்யன் சூல஬ென்஦ி  
  யமீ்஧ோம்ல஧ கோெம் ஧ி஬ீகஞ் ெி஬ி஧தம் ய஫ீிருநல்  
  தோம்஧ோங் கிருநி னிலயதனகு நோெிய ெம்஧ில஦தன.  
- ததலபனர் குணயோகடம் 
Action: 
 Stimulant 
 Stomachic 
 Antispasmodic 
 Carminative 
 emetic  
 disinfectant 
 
Alkaloids:  
 Acorin 
 Acoretin 
 Calamin 
 Starch 
 Calamen 
 Calamenol 
 Asarone   
 
POONDU 
 
Botanical name: Allium  sativum 
English name :Garlic 
Family : Alliaceae 
 
Organoleptic character: 
 
Taste                 : Acrid 
Potency             : Hot 
Division            : Acrid 
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ACTION: 
 Carminative 
 Stomachic 
 Tonic 
 Alterative  
 Stimulant 
 Expectorant 
 Diuretic 
Chemical constituents 
 Allicin 
 Allisatin 
 
AAMANAKU 
 
Botanical name : Ricinus communis 
English name     : Castor oil plant 
Family  : Euphorbiceae 
 
Organoleptic character: 
 
Taste  : Bitter 
Potency : Hot 
Division : Acrid 
 
General properties: 
 
  யோதத் நதோடக்லக யபநயோட்டோ நற்஧டிக்கு 
  கோதத்துக் கப்஧ோற் கடிப௅தந – சூதத்லதப் 
  த஧பண்டப் ஧ந்திக்கும் த஧திக்கு த஥ோய்க்கோட்லட 
  தனபண்ட நநன்஧ தி஦ிதன.  
- ததலபனர் நயண்஧ோ 
Action: 
 Anti vatha  
 Laxative 
 Emollient 
Alkaloids:  
 Ethanol 
 Ethyl ester 
 Triethyl citrate  
 Octadecanic acid 
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INTERNAL MEDICINE- RAJA ELATHY CHOORANAM 
 
 
       MILAGU- Piper nigrum     KIRAMBU-Syzygium aromaticum 
 
                             
 
 
 
 
 
 
 
 
    CHUKKU- Zingiber officinalis                         ELAM- Elattaria cardamum 
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              SUGAR                                               SIRUNAGAPPO- Mesua nagassarium  
                  
 
                                 
 
 
 
 
 
 
 
KOOGAINEER-Maranta Arundinaceae          THALISAPATHRI- Taxus buccata  
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EXTERNAL MEDICINE- NATHAICHOORI ENNAI 
 
     VELLULI- Allium sativum                             VASAMBU- Acorus calamus            
                         
  
 
 
 
 
 
 
 
 
AMANAKKU - Riccinus communis          NATHAICHOORI 
                                                                                                 Spermacoce hispida 
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TRIAL DRUGS 
Rajaelathy chooranam 
 
 
 
 
 
 
 
 
Nathaichoori Ennai 
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MATERIALS AND METHODS 
 
STANDARD OPERATING PROCEDURE:   
Source of trial medicine: 
           The required raw drugs for the trial medicines will be purchased from a well 
reputed country raw drug shop then raw drugs will be authenticated by the department of 
Medicinal botany National Institute of Siddha. Authenticated raw drugs will be purified 
separately and then the trial drugs will be prepared as per the literature in Gunapadam 
Laboratory of National Institute of Siddha. 
 
PREPARATION OF TRIAL DRUGS 
Internal Drug:  RAJAELATHY CHOORNAM 
 
INGRIDIENTS   
• Elam (Fruit of Elattaria cardomomum)         -  64 Varagan eadai   (269gm) 
• Chukku (Rizome of Zingeber officinale)               -  32 Varagan eadai    (134.4gm)  
• Koogai neer (Tuber of Maranta arundinaceae)     -  16 Varagan eadai    (67.2gm) 
• Thalisabathri (Abies spectabilis)                            -  8   Varagan eadai    (34gm) 
• Serunaga poo (Flower of Mesuna nagassarium)   -  4  Varagan eadai     (17gm)                           
• Milagu (Fruit of Piper nigrum)                              -  2 Varagan eadai      (8.4gm) 
• Kirambu (Flower of Syzygium aromaticum)          -  1 Varagan eadai      (4.2gm) 
• Sugar                                                                       -  1 ½ saer                  (420gm) 
 
PURIFICATION OF RAW DRUGS: 
Purification of Chukku: Soak in lime stone water and dry it in shade  then 
peel off the outer layer [Ref: Sarakugalin Suthee  Muraigal,  Pg .6] 
Purification of Milagu: Soak in butter milk for a period of 1 saamam (3 
hours) then allow it to dry.  [Ref: Sikicha  Rathina Deepam  Ennum Vaithiya  Nool, Page  
28] 
Purification of Kirambu: Dry it in sunlight and fry. [Ref: Sarakugalin  
Suthee  Muraigal  Page: 6]    
  
51 
 
Purification of Thalisabathri: Dry it in sunlight. [Ref: Sikicha Rathina  
Deepam  Ennum  Vaithiya  Nool,  Page  28] 
Purification of Sirunagapoo: Dry it in sunlight. [Ref: Sikicha Rathina  
Deepam Ennum  Vaithiya  Nool,  Page  28] 
Purification of Elam: Dry it in sunlight and fry. [Ref: Sarakugalin Suthee  
Muraigal,  Page:6] 
Purification of koogai kilangu : Dissolve in pure water for 7 times and 
filter it and dry it in sunlight. [Ref : Sikicha Rathina Deepam Ennum Vaithiya Nool. 
 
PREPARATION OF INTERNAL DRUG: 
METHOD OF PREPARATION: 
After purification of raw drugs powder them individually and then mix well 
together and finally add sugar. 
 
EXTERNAL DRUG 
Nathaichoori ennai: 
INGRIDIENTS: 
 
 Nathai choori vear (Root of Spermacoce hispida)             -    3palam (105gm) 
 
 Vasampu (Rhizome of Acorus calamus)                           -   ¾ palam (12gm) 
 
 Poondu (Bulb of Allium sativum)                                        -   ¼ palam (8.75gm) 
 
 Amanakku ennai (Oil of Ricinus communis)                      -      1 padi (1.34litre)   
 
 
Method of preparation: 
Grind the raw drugs mix it with castor oil and heat it until attaining suitable 
consistency. 
Drug storage: 
The drug Rajaelathy Chooranam is stored in a clean glass jar and Nathai choori 
Ennai is stored in a clean and dry narrow mouthed bottles.  
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Dispensing: 
The Rajaelathi Chooranam was given in packets and Nathai choori ennai was 
given in bottles. 
 
Varmam Points to be applied for the Patient: 
Kavuli Kaalam 
Vellai varmam 
Kaipuja poruthu varmam 
 
  PRECLINICAL STUDY 
CHEMICAL EVALUATION 
  Experimental procedure:  
5 g of Rajaelathy Chooranam was taken in a 250 ml of clean beaker and 50ml of 
distilled water was added to it. Then it was boiled well for about 10 min. Then it is 
allowed to cool and filtered in a 100 ml volumetric flask and made up to 100 ml with 
distilled water. This preparation is used for the qualitative analysis of acidic/basic radicals 
and biochemical constituents in it. 
 
Preparation of extract:  
5gm of Rajaelathy Chooranam is weighed accurately and placed in a 250ml clean 
beaker and 50ml of distilled water was added with it. Then it was boiled well for about 10 
minutes. Then it was allowed to cool and filtered in a 100ml volumetric flask and made 
up to 100ml with distilled water. The bio-chemical analysis of Rajaelathy Chooranam 
was done at Biochemistry lab, National Institute of  Siddha, Chennai-47. 
 
Preliminary test for Copper, Sodium, Silicate and Carbonate: 
 
Test for Silicate: 
a. A little (500mg) of the sample is shaken well with distilled water. 
b. A little (500mg) of the sample is shaken well with con. HCl/Con. H2So4. 
 
Action of Heat: A small amount (500mg) of the sample is taken in a dry test tube 
and heated gently at first and then strong. 
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Action of Heat: A small amount (500mg) of the sample is taken in a dry test tube 
and heated gently at first and then strong. 
 
Flame Test: A small amount (500mg) of the sample is made into a paste with con. 
HCl in a watch glass and introduced into non-luminous part of the Bunsen flame. 
 
Ash Test: A filter paper is soaked into a mixture of sample and dil. cobalt nitrate 
solution and introduced into the Bunsen flame and ignited. 
 
Test For Acid Radicals 
 Test For Sulphate: 2ml of the above prepared extract was taken in a test tube 
and 2ml of 4% dil. ammonium oxalate solution was added. 
 Test For Chloride: 2ml of the above prepared extracts was added with 2ml of 
dil-HNO3 until the effervescence ceases off. Then 2 ml of silver nitrate solution was 
added. 
Test For Phosphate: 2ml of the extract was treated with 2ml of con.HNo3 and 
2ml of dil. ammonium molybdate solution.   
 Test For Carbonate: 2ml of the extract was treated with 2ml dil. magnesium 
sulphate solution 
 Test For Nitrate: 1gm of the substance was heated with copper turning and 
concentrated H2SO4 and viewed the test tube vertically down. 
 Test For Sulphide: 1gm of the substance was treated with 2ml of con. HCL 
 Test For Fluoride & Oxalate: 2ml of extract was added with 2ml of dil. Acetic 
acid and 2ml dil.calcium chloride solution and heated. 
 Test For Nitrite: 3drops of the extract was placed on a filter paper, on that-2 
drops of dil.acetic acid and 2 drops of dil. Benzidine solution were placed. 
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Test For Basic Radicals 
Test For Lead: 2ml of the extract was added with 2ml of dil.potassium iodine 
solution. 
Test For Copper: One pinch (50mg) of substance was made into paste with con. 
HCl in a watch glass and introduced into the non-luminous part of the flame. 
Test For Aluminium: In the 2ml of extract dil.sodium hydroxide was added in 5 
drops to excess. 
 
Test For Iron: 
 
a. To the 2ml of extract add 2ml of dil. ammonium solution 
    b. To the 2ml of extract 2ml thiocyanate solution and 2ml of con HNo3 is added 
 
Test For Zinc: In 2ml of the extract dil.sodium hydroxide solution was added in 5 
drops to excess and dil.ammonium chloride was added.  
Test For Calcium: 2ml of the extract was added with 2ml of 4% dil.ammonium 
oxalate solution  
Test For Magnesium: In 2ml of extract dil.sodium hydroxide solution was added 
in drops to excess. 
Test For Ammonium: In 2ml of extract 1 ml of Nessler's reagent and excess of 
dil. sodium hydroxide solution were added. 
Test For Potassium: A pinch (25mg) of substance was treated with 2ml of dil. 
sodium nitrite solution and then treated with 2ml of dil. cobalt nitrate in 30% dil.glacial 
acetic acid. 
Test For Sodium: 2 pinches (50mg) of the substance was made into paste by 
using HCl and introduced into the blue flame of Bunsen burner. 
Test For Mercury: 2ml of the extract was treated with 2ml of dil.sodium 
hydroxide solution.  
Test For Arsenic: 2ml of the extract was treated with 2ml of dil.sodium 
hydroxide solution. 
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Other constituents 
Test For Starch: 2ml of extract was treated with weak dil. iodine solution  
Test For Reducing Sugar: 5ml of Benedict's qualitative solution was taken in a 
test tube and allowed to boil for 2 minutes and added 8 to 10 drops of the extract and 
again boil it for 2 minutes.  
 
Test For The Alkaloids: 
 
a) 2ml of the extract is treated with 2ml of dil. potassium iodide solution.    
b) 2ml of the extract is treated with 2ml of dil.picric acid. 
Test For Tannic Acid: 2ml of extract was treated with 2ml of dil. ferric chloride 
solution 
Test For Unsaturated Compound: In the 2ml of extract 2ml of dil. Potassium 
permanganate solution was added.  
Test For Amino Acid: 2 drops of the extract was placed on a filter paper and 
dried well, and then 20ml of Burette reagent was added in it. 
 
TOXICITY STUDIES OF RAJAELATHY CHOORANAM 
To evaluate the safety profile of Raja elathy chooranam short term and long term 
toxicity study carried out as followed. The principles of laboratory animal care were 
followed and the Institutional Animal Ethical Committee approved the use of animals 
and the study design. IAEC registered and approval number: (IAEC). 
(NIS/IAEC/III/07/29092016 dated 29.09.2016) for Short term toxicity study and Long 
term toxicity study. 
 
Experimental Animals: 
Species              : Wistar albino Rats 
Sex      : Male and Female  
Age/weight  at start of test  : 6 weeks/140-160g b.wt 
Acclimatization Period  : 7 days prior to dosing 
Housing    : Polypropylene cages with bedding with    
husk. 
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Husbandry    : 12-h light/12-h dark cycle/ Room  
                                                             temperature 22°C±3°C and relative  
humidity 30–70% 
Feed and Water   :  Rodent pelleted feed RO purified water   
ad libitum   
Identification   : Animals will be kept in Polypropylene   
cages and numbered  
 
Experimentation Details of Short term Toxicity Study: 
 
Groups/Treatment regimen   : Grouped by randomisation 
Test Guideline     : WHO 
Length of exposure to test substance  : 1 day 
No of Animals     : 5 Female+ 5 Male / group 
Control group     : Vehicle (water) 
Test groups     :  Rajaelathy Chooranam2000 mg/kg.b.wt  
 
The wistar albino rats of both sex weighing 150-200g will be obtained from 
authorized animal breeders of animal laboratory in TANUVAS, Madavaram, Chennai and 
stocked in animal house at National Institute of Siddha, Chennai.  Animals will be house 
in cage at 22°C±3°C andrelative humidity 30–70% and have free access to standard rat 
pellet diet (Sai Meera Foods Pvt. Ltd., Bangalore). The animals will be dosed with 
Rajaelathy chooranam by oral for one day and monitored for behavioural parameters for 
the first 4 hours after drug administration. Body weight of the animal will be monitored at 
weekly intervals. The animals that the die within this period will be subjected to 
necropsy. Remaining animals will be weighed and sacrificed under the injection of 
Pentathal Sodium on the 15
th
day of the Study period. The toxicological effects were 
assessed on the basis of mortality. 
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Preparation of Test Drug Doses: 
 
Groups No. of Rat 
Group I: Vehicle control (water) 10 (5M+5F) 
Group II: test drug (RC)- 2000 mg/kg b.wt 10 (5M+5F) 
 
*RC- Rajaelathy chooranam 
Route of administration 
Oral route were selected because it is the normal route of clinical administration. 
 
Administration of Dose 
The animals were kept in fasting (only food was with held) for12hrs and weighed 
prior to dosing. Three animals were used for each step. A single dose of the solution 
(2000mg/kg) was consecutively administered by oral gavage using intubation  cannula. 
Food was with held for another 4hrs after dosing and administration of drug. As per the 
guide line the starting dose level was taken as 2000mg/kg bodyweight. 
 
Observations: 
Observations were made and recorded systematically and continuously observed 
after the substance administration as per the guidelines.  
 ½ hour, 1 hour, 2 hour, 4 hour and upto 24 hours observation. 
 All rats will be observed twice daily on week days for 14 days. 
 Body weight per weekly one times. 
 Feed intake per day 
 
Cage side observation  
The animals were monitored for behavioral parameters like, Alertness, 
Aggressiveness, piloerection, Grooming, Gripping, Touch Response, Motor Activity, 
Tremors,  Convulsions, Muscle  Spasm, Catatonia, Muscle relaxant,  Hypnosis Analgesia, 
Lacrimation, Exophthalmos, Diarrhea, Writhing,  Respiration, Mortality 
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Necropsy: 
Necropsy includes gross examinations of the external surface of the body, all 
orifices, cranial, thoracic and abdominal cavities and their contents. Brain, eye, lungs, 
heart, spleen, liver, kidneys, adrenals and uterus of all animals. 
 
Experimentation Details of Long term Toxicity Study: 
Experimental Animals: 
Species            : Wistar Albino Rats 
Sex      : Male and Female 
Age/weight  at start of test  : 6 weeks/140-160g b.wt 
Acclimatization Period  : 7 days prior to dosing 
Housing    : Polypropylene cages with bedding with   
       husk  
Husbandry    : 12-h light/12-h dark cycle/ 
       Room temperature 22°C±3°C and 
       relative humidity 30–70% 
Feed and Water  : Rodent pelleted feed RO purified water  
           ad libitum 
Identification   : Animals will be kept in Polypropylene cages   
                                            and numbered 
 
Experimentation Details of Long term Toxicity Study: 
 
Groups/Treatment regimen  : Grouped by randomisation 
Test Guideline    : WHO 
Length of exposure to test substance : 90 days 
No of Animals    : 10 Female+10 Male / group 
Control group    : Vehicle (water) 
Test groups    : Rajaelathy Chooranam (Low dose, Mid                 
                                           dose, High dose)                                                  
The 80 Wistar albino rats of both sex selected randomly. The animals were 
divided into four groups. Each group consist at 20 animals.  
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First group treated as vehicle control and second, third and fourth groups were 
treated with Rajaelathy chooranam Low dose (180 mg), Mid dose (900 mg) and High 
dose (1800 mg) respectively. The animals were dosed with Rajaelathy chooranam by oral 
for 90 days and is monitored for behavioural parameters for the first 4 hours after drug 
administration. Body weight of the animal was be monitored at weekly intervals. The 
animals that die within this period was be subjected to necropsy. Remaining animals was 
be weighed and sacrificed under the injuction of Pentathal Sodium on the on the 91
st  
day 
of the study. Blood will be collected from the anesthetized animals from Abdominal aorta 
and the following investigations like Haematology, Biochemical analysis and 
Histopathology are done. 
 
They above dose were fixed from the result of Short term toxicity study 
 
Groups No. of Rats 
Group I:  Vehicle control (water) 20(10M+10F) 
GroupII:Test drug (RC)- low dose (180mg/kg b.wt) 20(10M + 10F) 
GroupIII: Test drug(RC) - Mid dose (900mg/kg.b.wt) 20(10M +10F) 
GroupIV:Test drug(RC) High dose (1800 mg/kg b.wt) 20(10M +10F) 
 
*RC- Rajaelathy chooranam 
 
Preparation and administration of dose: 
 
Rajaelathy Chooranam was d i s s o l v ed  i n  water  t o  obtain concentrations of 
1800mg/ml. It was administered to animals at the dose levels of180mg/kg b.wt, 
900mg/kg b.wtand1800mg/kg b.wt. The test substance solutions were freshly prepared 
every two days once for 90days. The control animals were administered with water as 
vehicle. Administration was given by oral, once daily for 90 consecutive days.  
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Observations: 
Experimental animals were kept under observation throughout the course of study 
For the following 
 All rats will be observed twice daily on week days for 90 days 
 Body weight per weekly one times 
 Feed intake per day 
 
Cage side observation   
The animals were monitored for behavioral parameters like, Alertness, 
Aggressiveness, pilo erection, Grooming, Gripping, Touch Response, Motor Activity, 
Tremors, Convulsions, Muscle Spasm, Catatonia, Muscle relaxant, Hypnosis Analgesia, 
Lacrimation, Exophthalmos, Diarrhea, Writhing,  Respiration, Mortality. 
 
Gross necropsy: 
Gross necropsy includes examinations of the external surface of the body, all 
orifices, cranial, thoracic and abdominal cavities and their contents. Brain, eye, lungs, 
heart, spleen, liver, kidneys, adrenals and uterus of all animals. 
 
Laboratory Investigations: 
On the 91
st 
day, the animals were fasted over night, then anesthetized to collect 
blood samples from the abdominal aorta in two tubes: one with EDTA for the 
hamatological parameters, another one without any anti coagulant and was centrifuged at 
4000rpm at4°C for10minutes to obtain these rum for biochemical parameters. 
 
Hematological Investigations: 
Blood samples of control and experimental rats were analyzed for hemoglobin 
(Hb), total red blood corpuscles (RBC), white blood corpuscles (WBC) count, Mean 
corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH) were calculated. 
 
Biochemical Investigations: 
Serum samples of control and experimental rats were analyzed for Bilirubin, Uric 
Acid, Creatinine, Triglyceride, Total Cholesterol, HDL, LDL, VLDL, using standard 
methods. Activities of glutamate oxalo acetate transaminase / Aspartate amino 
transferase (GOT/AST) and glutamate pyruvate transaminase / Alanine amino transferase 
(GPT/ALT) were estimated as perthe colorimetric procedure. 
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Necropsy: 
All the animals were sacrificed on the 91
st 
day. Necropsy of all animals was 
carried out and the weights of the organs including liver, kidneys, spleen, brain, heart, 
lungs and stomach were recorded. 
 
Histopathology: 
The organs included liver, kidneys, spleen, brain, heart, lungs and stomach of the 
animals were preserved, and they were subjected to histo-pathological examination. 
Histo-pathological investigation of the vital organs was done. The organ pieces  
(3-5umthick) of the three different (low, mid, high) dose level was preserved and was 
fixed in 10% formalin for 24 had washed in running water. Samples were dehydrated in 
an auto technique on and then cleared in benzene to remove absolute alcohol. Embedding 
was done by passing the cleared samples through three cups containing molten paraffin 
at 50
oC and then in a cubical block of paraffin made by the “L” molds. It was followed by 
microtome and the slides were stained with Haematoxylin-eosin. 
 
CLINICAL STUDY   
Study design: 
Study Type                :  An open clinical trail 
Study Place             :  OPD and IPD of Ayothidoss Pandithar Hospital,  
     National Institute of Siddha, 
  Tambaram Sanatorium, Chennai - 47. 
Study Period  :  18 Months 
Sample Size  :  40 patients (Both IPD & OPD) 
 
Subject Selection: 
Patients reporting with symptoms of Kumbavaatham will be subjected to 
screening using screening proforma then they will be involved for the trial by fulfilling 
the inclusion criteria.  
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Inclusion Criteria: 
 Age : 20-65yrs 
  Sex : Both male and female 
  Pain and stiffness in shoulder  region 
 Restricted movements of shoulder joint 
 Exacerbation of pain on movement 
 Restricted movements of shoulder joint(abduction and external rotation) 
 With or without pain radiating to upper arm 
 Patients willing undergo radiological investigation and give blood samples for 
laboratory investigations 
 Patient willing to sign the informed consent stating that he/she will consciously 
stick to the treatment but can opt out of the trial of his/her own conscious 
discretion.  
 
Exclusion Criteria: 
 Diabetes Mellitus 
 Pregnancy and lactation 
 Cardiac disease 
 Septic arthritis 
 Malignant hypertension 
 Gonococcal arthritis 
 Fracture and dislocations of shoulder joint 
 Cervical spondylosis 
 Any other chronic illness 
 
Withdrawal Criteria: 
 Intolerance to the drug and development of adverse reactions during drug trial. 
 Poor patient compliance and defaulters. 
 Patient turning unwilling to continue in the course of clinical trial. 
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Tests and Assessments: 
A. Clinical assessment  
B. Laboratory Investigations 
C. Radiological investigations 
D. Siddha system examination 
A. Clinical Assessment 
 Pain and stiffness in Shoulder joint. 
 With or without radiation of pain to upper arm. 
 Exacerbation of pain on movements. 
 Restricted movements [abduction and external rotation] 
 
B. LABORATORY INVESTIGATIONS: 
BLOOD: 
 H B                                                    
 Total WBC Count                                              
 DC -   Polymorphs: 
 Lymphocytes  
 Eosinophils  
 Monocytes  
 Basophils  
 Total RBC count 
 ESR   ½ hr: 
          1hr:   
 Blood sugar -  Fasting : 
                        Post prandial: 
Serum cholesterol, uric acid 
            CRP, RA factor, ASO titre 
RENAL FUNCTION TESTS: 
             Blood Urea 
             Serum Creatinine 
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LIVER FUNCTION TESTS: 
  Serum total bilirubin, Direct bilirubin & Indirect bilirubin 
              Serum Alkaline phosphatase 
              SGOT & SGPT 
 
URINE: 
       Urine sugar – Fasting & Post prandial: 
       Albumin 
       Deposits 
 
D. RADIOLOGICAL INVESTIGATION 
               X - Ray Shoulder joint: AP View. 
SIDDHA PARAMETERS: 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram  
 
DATA COLLECTION FORMS: 
 Required information will be collected from each patient by using the following 
forms: 
FORM I  : Screening and Selection form 
FORM II  : Clinical Assessment form 
FORM III          : Laboratory Investigation form 
FORM IV         : Drug compliance form 
FORM V  : Patient information form 
FORM VI         : Informed consent form 
FORM VII        : Withdrawal / Pharmaco vigilance / adverse form 
FORM VIII      : Dietary Advice form 
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STUDY ENROLLMENT:  
Patients reporting at the OPD with the clinical symptoms of Kumbavatham were 
examined clinically for enrolling in the study based on the inclusion and exclusion 
criteria.  
The patients who were enrolled would be informed (Form V) about the study, trial 
drug, possible outcomes and the objectives of the study in the language and terms 
understandable to them and informed consent would be obtained in writing from them in 
the consent form (Form VI).  
Complete clinical history, complaints and duration, examination findings and 
laboratory investigations recorded in the prescribed Proforma. Screening Form-I were 
filled up: Form – II and Form – III will be used for recording the   patient history, clinical 
examination of symptoms, signs and laboratory Investigation. If there any abnormal 
Laboratory Reports obtained then excluded from the study. 
 Patients were advised to take the trial drug and to follow the appropriate dietary 
advice. (Form -VIII) 
 
CONDUCT OF THE STUDY: 
Purgation with Meganaatha Kuligai - 2 early morning with Hot Water given for 
balancing the deranged Mukuttram before starting the treatment.  
(Ref: Siddha formulary of India. Part- I) 
 
Next day onwards the trial drug, Rajaelathy Chooranam (Internal) and 
Nathaichoori Ennai (external) given continuously for 48 days. OPD patients are 
requested to visit the hospital once in 7 days. In each and every visit clinical assessment is 
done and prognosis was noted in the Prescribed Proforma. For IPD Patients clinical 
assessment was done daily. 20 patients were given Varmam treatment along with trial 
medicines and the remaining 20 were given medicine only. If there is need of IPD 
patients admitted in the ward for the clinical assessment. Laboratory investigations and 
Radiological investigations are done before and after the trial. At the end of the treatment, 
the patient advised to visit the OPD for follow-up. Defaulters not be allowed to continue 
and be withdrawn (Form VII) from the study. 
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DATA ANALYSIS: 
 After enrolling the patient for the study, a separate file for each and every patient 
opened and all forms kept in the file. Study No and Patient No written on the top of file 
for easy identification. Whenever the patient visits OPD during the study period, the 
respective patient‟s file taken and necessary entries made at the assessment form or other 
suitable form. The screening forms filed separately. The data recordings monitored for 
completion and adverse event by HOD and pharmaco - vigilance committee. All forms 
were scrutinized in presence of Investigators by Sr.Research Officer (Statistics) for 
logical errors and incompleteness of data to avoid any bias. 
 
ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT 
In this study, no adverse reactions were observed during the course of treatment. 
 
DATA ANALYSIS: 
After enrolling the patients in the study, a separate file for each patient maintained 
and all forms kept in the file. Study No and patient‟s No entered on the top of the file for 
easy identification. Whenever the patients visit OPD during the study period, necessary 
entries made at the assessment forms. The screening forms filled separately.  
All forms were scrutinized by Senior Research Officer (Statistics) for logical 
errors and incompleteness of data to avoid any bias. 
 
OUTCOME: 
Shoulder improvement assessed by following assessment: 
 
Shoulder Pain and disability index (SPADI) 
Source:  
          Roach KE, Budiman-Mak E, Songsiridej N, Lertratanakul Y. Development of a 
shoulder pain and disability index. Arthritis Care Res. 1991 Dec;4(4):143-9. 
 
The Shoulder Pain and Disability Index (SPADI) is a self-administered 
questionnaire that consists of two dimensions, one for pain and the other for functional 
activities.  
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The pain dimension consists of five questions regarding the severity of an 
individual's pain. Functional activities are assessed with eight questions designed to 
measure the degree of difficulty an individual has with various activities of daily living 
that require upper-extremity use. The SPADI takes 5 to 10 minutes for a patient to 
complete and is the only reliable and valid region-specific measure for the shoulder. 
 
SCORING INSTRUCTIONS 
 
              To answer the questions, patients place a mark on a 10cm visual analogue scale 
for each question. Verbal anchors for the pain dimension are „no pain at all‟ and „worst 
pain imaginable‟, and those for the functional activities are „no difficulty‟ and „so difficult  
it required help‟. The scores from both dimensions are averaged to derive a total score. 
 
INTERPRETATION OF SCORES 
Total pain score:   / 50 x 100 = % 
(Note: If a person does not answer all questions divide by the total possible score, eg. if 1 
question missed divide by 40) 
Total disability score:   / 80 x 100 = % 
 (Note: If a person does not answer all questions divide by the total possible score, eg. if 1 
question missed divide by 70) 
Total Spadi score:   / 130 x 100 = % 
 (Note: If a person does not answer all questions divide by the total possible score, eg. if 1 
question missed divide by 120) 
The means of the two subscales are averaged to produce a total score ranging from 0 
(best) to 100 (worst). 
Minimum Detectable Change (90% confidence) = 13 point  
(Change less than this may be attributable to measurement error) 
Shoulder Pain and Disability Index (SPADI)  
Please place a mark on the line that best represents your experience during the last 
week attributable to your shoulder problem.  
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PAIN SCALE 
 
How severe is your pain?  Circle the number that best describes your pain where: 
 0 = no pain and 10 = the worst pain imaginable 
 
DISABILITY SCALE  
How much difficulty do you have?  
Circle the number that best describes your experience where: 0 = no difficulty and 10 = so 
difficult it requires help.  
 
OUTCOME: 
 Very Good –76-100% reduction of SPADI Score 
 Good – 51-75% reduction in SPADI Score 
 Moderate – 26-50% reduction in SPADI Score 
 Mild – 0-25% SPADI Score 
At its worst? 0 1 2 3 4 5 6 7 8 9 10 
When lying on the involved side? 0 1 2 3 4 5 6 7 8 9 10 
Reaching for something on a high 
shelf? 
0 1 2 3 4 5 6 7 8 9 10 
Touching the back of your neck? 0 1 2 3 4 5 6 7 8 9 10 
Pushing with the involved arm? 0 1 2 3 4 5 6 7 8 9 10 
Washing your hair? 0 1 2 3 4 5 6 7 8 9 10 
Washing your back? 0 1 2 3 4 5 6 7 8 9 10 
Putting on an undershirt or jumper? 0 1 2 3 4 5 6 7 8 9 10 
Putting on a shirt that buttons down the front? 0 1 2 3 4 5 6 7 8 9 10 
Putting on your pants? 0 1 2 3 4 5 6 7 8 9 10 
Placing an object on a high shelf? 0 1 2 3 4 5 6 7 8 9 10 
Carrying a heavy object of 10 pounds (4.5 
kilograms) 
0 1 2 3 4 5 6 7 8 9 10 
Removing something from your back pocket? 0 1 2 3 4 5 6 7 8 9 10 
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QUALITATIVE ANALYSIS 
PHYSICO-CHEMICAL ANALYSIS 
Table-1: Colour, nature  of Rajaelathy Chooranam 
 
Table-2: Test for Basic radicals 
S.no Procedures      Rajaelathy Chooranam 
 
1. Test for Ammonium  
- 
2. Test for Sodium - 
 
3. Test for Magnesium - 
 
4. Test for Aluminium - 
 
5. Test for Potassium + 
 
S.no Parame
ters 
Results Method of Testing 
 
1. Colour Yellowish green By visual 
 
2. Odour Odour( Sweet 
Smell) 
Olfactory examination 
 
 
3. Solublity  Soluble in honey 
 Insoluble in water 
Qualitative 
 
 
4
. 
Nature Powder By visual 
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6. Test for Calcium + 
 
7. Test for Ferrous iron  
+ =+ 
8. Test for Copper  
- 
9. Test for Zinc  
- 
10. Test for Arsenic - 
 
11. Test for Mercury - 
 
12. Test for Lead - 
 
 
 
Inference 
Bio-chemical analysis for basic radicals reveals that Rajaelathy Chooranam 
contains Potassium, Calcium and Iron. 
Table-3: Test for Acidic radicals 
S.no Procedures Rajaelathy Chooranam 
 
1. Test for Sulphate  
+ 
2. Test for Chloride + 
 
3. Test for Phosphate + 
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4. Test for Flouride & Oxalate  
- 
5. Test for Nitrite + 
 
Table-4: Test for Acidic radicals 
S.no Procedures Rajaelathy Chooranam 
 
1. Test for Starch + 
 
2. Test for Reducing sugar + 
 
3. Test for Alkaloids + 
 
4. Test for Amino acids _ 
 
5. Test for Tannic acids + 
 
6. Test for type of compounds  
                     No Change 
 
Inference 
 Bio-chemical analysis for acid radicals reveals that Rajaelathy Chooranam 
contains Chloride, sulphide, phosphate, nitrite Starch, Reducing sugar, Alkaloid, tannic 
acid. 
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Toxicity study Results of Rajaelathy Chooranam 
Table: 5 Dose finding experiment and its behavioural Signs of Toxicity 
No Dose 
Mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
 
 
 
1. Control + - - + + + - - - - - - - - - - - - + - 
 
2. 2000 + - - + + + - - - - - - - - - - - - + - 
 
 
1.Aletness 2.Aggressiveness 3.pilo erection 4.Grooming 5.Gripping 6.Touch Response 7. 
Motor Activity 8.Tremors 9.Convulsions 10.Muscle Spasm 11.Catatonia 12.Muscle 
relaxant 13.Hypnosis 14.Analgesia 15.Lacrimation 16.Exophthalmos 17.Diarrhoea 
18.Writhing 19. Respiration 20.Mortality 
+ Presence of Activity  
- Absence of Activity 
 
All the data were summarized in the form of table revealed no abnormal signs and 
behavioural changes in rats at the dose of 2000 mg/kg body weight administered orally 
                                         
Short term Toxicity study 
In short term toxicity study, the test drug at Rajaelathy Chooranam for single 
dose(2000mg/kg b.wt) was administered. 
There was no mortality or signs of toxicity observed after dosing Rajelathy 
Chooranam 2000mg/kg body weight during the study period of 14 days. This indicates 
that the LD50 of Rajaelathy Chooranam is more than 2000mg/kg b.wt. 
There was no changes in skin and fur, eyes and mucous membranes of all animals.  
The eating, drinking habit, sleep pattern, locomotion were normal in all animals and no 
changes in body weight as compared to control group. 
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At the end of the 14
th
 day necropsy was done and there was no abnormality seen in 
test groups as compared to control group during the examination. 
    
 
Long term Toxicity study 
Haematological report: 
  There is no significant changes in haematological and serological parameters of 
the control and test group after the administration of trial drug.   
 
Food (g/day) intake of albino rats exposed to Rajaelathy Chooranam 
Dose 
(mg/kg/day) 
 
 
Control 
 
LD 
 
MD 
 
HD 
1st day 5.54±0.21 6.11±0.21 5.59±0.25 6.2±0.15 
15 th day 6.3±0.18 6.4±0.21 6.7±0.27 7.27±0.27 
30 th day 6.7±0.27 7.07±0.17 6.65±0.18 7.45±0.24 
45 th day 7.07±0.17 7.08±0.18 7.07±0.17 7.45±0.25 
60 th day 7.07±0.17 7.27±0.27 7.37±0.24 7.45±0.25 
75 th day 7.27±0.27 7.37±0.24 7.60±0.28 7.63±0.25 
90 th day 7.60±0.28 7.63±0.25 7.95±0.11 7.75±0.13 
 
Values are mean± S.D. (Dunnett‟s test).*P<0.05,**P<0.01,N=12 
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Water (ml/day) intake of albino rats exposed to Rajaelathy Chooranam 
Dose 
(mg/kg/day) 
Control LD MD HD 
1st day 
(ml/rat) 
9.15±0.13 8.13±0.12 9.15±0.12 9.20±0.15 
15 th day 
(ml/rat) 
9.52±0.21 8.13±0.12 8.13±0.12 8.13±0.12 
30 th day 
(ml/rat) 
8.13±0.12 8.13±0.12 9.52±0.21 8.13±0.12 
45 th day 
(ml/rat) 
9.96±0.11 9.25±0.17 9.15±0.12 8.13±0.12 
60 th day 
(ml/rat) 
9.96±0.11 9.52±0.21 9.96±0.11 9.52±0.21 
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75 th day 
(ml/rat) 
9.96±0.11 9.96±0.11 10.30±0.13 9.96±0.11 
 
90 th day 
(ml/rat) 
9.96±0.11 10.30±0.13 9.96±0.11 9.96±0.11 
 
Values are mean± S.D. (Dunnett‟s test).*P<0.05,**P<0.01,N=12 
 
 
 
 
 
Body weight (g) changes of albino rats (female) exposed to Rajaelathy 
Chooranam 
Dose 
(mg/kg/day) 
 
 
Control 
 
LD 
 
MD 
 
HD 
 
1st day 
 
134.16±4.21 
 
138.12±3.50 
 
140.2±2.13 
 
138.14±2.46 
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15 th day 
 
 
164.16±4.21 
 
158.45±2.16 
 
162.36±5.07 
 
157.25±1.67 
 
30 th day 
 
 
190.83±6.14 
 
189.16±6.23 
 
192.12±4.21 
 
189.25±5.26 
 
45 th day 
 
 
209.16±5.07 
 
206±4.21 
 
210.2±6.30 
 
207±3.16 
 
60 th day 
 
 
235.83±4.21 
 
237.38±6.14 
 
240.24±6.14 
 
239.68±4.21 
 
75 th day 
 
 
270.83±6.30 
 
272.5±5.02 
 
278.8±2.36 
 
276.26±6.24 
 
90 th day 
 
 
315.5±6.44 
 
318.24±6.12 
 
320.6±5.07 
 
318.28±1.36 
 
Values are mean± S.D. (Dunnett‟s test).*P<0.05,**P<0.01,N=12 
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Body weight (g) changes of albino rats (male) exposed to 
Rajaelathy Chooranam 
Dose 
(mg/kg/day) 
 
 
Control 
 
    LD 
 
    MD 
 
      HD 
 
1st day 
 
139.33±4.13 
 
 
142.24±4.12 
 
152.16±2.45 
 
148.16±6.27 
 
15 th day 
 
 
173±5.79 
 
174.12±5.26 
 
178.16±5.79 
 
176±5.12 
 
30 th day 
 
 
203±5.79 
 
204.16±4.23 
 
202.18±9.12 
 
206.33±2.4 
 
45 th day 
 
 
236.16±9.24 
 
239±9.24 
 
239.23±8.28 
 
240.25±9.24 
 
60 th day 
 
 
288.66±9.24 
 
292.25±6.23 
 
297.26±5.20 
 
296.67±2.67 
 
75 th day 
 
 
319.5±8.50 
 
 
320.1±9.28 
 
326.5±4.13 
 
324.13±4.12 
 
90 th day 
 
 
359.5±9.71 
 
 
352.18±6.58 
 
348.16±7.02 
 
347.4±8.50 
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Values are mean± S.D. (Dunnett‟s test).*P<0.05,**P<0.01,N=12 
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Histopathology of Brain 
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Heart  
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High Power Magnification 40X 
 
 
 
 
 
 
81 
 
Histopathology of Lung  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Stomach  
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Histopathology of Liver  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Kidney  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Spleen  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Uterus  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Ovary  
Low Power Magnification 10X 
 
 
 
High Power Magnification 40X 
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    Histopathology Report 
 
Group Id: C1HFH 
Brain 
 No signs of pyknosis and perineural vacuolization 
 No signs of edema or degeneration were observed. 
 Arrangement of neurons on cerebral cortex appears normal and dense 
Heart 
 Appearance of cardiomyocyte was normal with dark nuclear region. The nuclei of 
muscle fibers appear oval arrangement 
 No evidence on accumulation of adipose tissue on interstitium 
 No evidence of atherosclerosis and thrombosis 
Lung 
 Pneuomocyte and capillary appears normal 
 Alveolar sac and septa appears normal with signs of degeneration 
 Pleura and brochioles appears normal 
 Pulmonary vessels and bronchioles appears normal 
Stomach 
 Pyloric and fundus zone of stomach appear normal 
 The continuity of mucosa was normal with no evidence of ulceration 
Liver 
 Increased sinusoidal space with vacuolated hepatocytes were observed 
occasionally 
 The cytoplasm of some cells shows rare empty vacuole-type spaces 
Kidney 
 Distinct tubular congestion were observed 
 Derangement in Interstitial connective tissue was observed 
Spleen 
 Marginal sinus (MS) of the rat and its sinus lining cells appears normal 
 Erythropoietic cells (EP) are scattered throughout the red pulp of both the 
samples. No abnormalities found in lymph node of both the samples 
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Uterus 
 Appearance of endometrium, myometrium and uterine glands was normal.  
 Endometrial gland, epithelium and blood vessels appears normal 
Ovary 
 Sequential arrangement of granulosa cells arounds oocyte was normal and regular 
 Follicular cells, cytoplasm and nucleus appears normal 
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Histopathology Report 
 
Group Id: C1HFH 
Brain 
 Brain showing intact molecular and granular layer of neuronal cells 
 Arrangement of the neurons appears regular with no signs of degeneration or 
apoptotic changes 
Lung 
 Lung parenchyma appears normal with regular arrangement of alveoli and 
alveolar sac with no signs of lymphocyte infiltration and pulmonary fibrosis 
Heart 
 Perfectly -arranged myocardial fibers, clear transverse striation and normal 
structure were observed. 
 Appearance of cardiomyocyte was normal with dark nuclear region. The nuclei of 
muscle fibers appear oval arrangement 
Stomach 
 Lamina propria appears normal with no evidence of infiltration and inflammation 
 Mucosal wall appears normal with regular arrangement of connective tissue 
Liver 
 Hepatocyte appears with dark pigment chromatin in centri lobular and periportal 
region 
 Hepatic sinusoid and hepatic cord was normal 
Kidney 
 Glomerular cell integrity, basement membrane and nephrotic bundle appears 
normal 
 No signs of lesion or inflammation were observed 
 Proximal and distal convoluted tubule appears normal 
Spleen 
 Marginal vascular zone radiated in between red and white pulp 
 Appearance of splenic red pulp was normal 
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Uterus 
 Arrangement of stratum basale, functionale and surface epithelium seems normal 
 Endometrial gland, epithelium and blood vessels appears normal 
 
Ovary 
o •Histopathological analysis of ovary showing normal corpus luteum (CL) 
and Primordial follicles with few mature ovarian follicles with no signs of 
abnormality. 
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Histopathology of Brain  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Heart  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Lung  
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Histopathology of Stomach  
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Histopathology of Liver  
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Histopathology of Kidney  
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Histopathology of Spleen  
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Histopathology of Testes  
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High Power Magnification 40X 
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Histopathology Report 
 
Group ID: C1HMH 
Brain 
 Primary dendrites and glial cells appears normal 
 The CA zones of brain are filles with densely packed Pyramidal cells  
Heart 
o No evidence on accumulation of adipose tissue on interstitium 
o No evidence of atherosclerosis and thrombosis 
Lung 
 No signs of airway secretion and bronchial secretion 
 Bronchial blood vessels and connective tissue appears normal with no sings of 
pulmonary edema 
Stomach 
 No signs of ulcer and glandular degeneration were observed 
 Appearance of Sub-mucosa and gastric glands appear normal 
Liver 
 Appearance of portal vein was normal  
 Appearance of hepatic cord was normal and radial in nature, no signs of cellular 
degeneration 
Kidney 
 Glomeruli appears hypertrophic 
 No signs of lesion or inflammation were observed 
 Proximal and distal convoluted tubule appears normal 
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Spleen 
 No signs of perivascular inflammation 
 Appearance of splenic sinuses, Splenic cord and endothelial orientation was 
normal 
TESTES 
 Appearance of leydig cells, interstitial tissue , seminiferous tubule, Sertoli cells 
and spermatogonia were normal 
 No signs of interstitial fibrosis were observed  
 Sperm oriented towards the center of sertoli cells with cluster of tail projected 
outside was observed 
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Histopathology of Brain  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Heart  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Lung  
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High Power Magnification 40X 
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Histopathology of Stomach  
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Histopathology of Liver  
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Histopathology of Kidney  
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Histopathology of Spleen  
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Histopathology of Uterus  
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Histopathology of Ovary  
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Histopathology Report 
 
Group Id: C1LFH 
Brain 
 No signs of pyknosis and perineural vacuolization 
 No signs of edema or degeneration were observed. 
 Arrangement of neurons on cerebral cortex appears normal and dense 
Heart 
 Appearance of cardiomyocyte was normal with dark nuclear region. The nuclei of 
muscle fibers appear oval arrangement 
 No evidence on accumulation of adipose tissue on interstitium 
 No evidence of atherosclerosis and thrombosis 
Lung 
 Pneuomocyte and capillary appears normal 
 Alveolar sac and septa appears normal with signs of degeneration 
 Pleura and brochioles appears normal 
 Pulmonary vessels and bronchioles appears normal 
Stomach 
 Pyloric and fundus zone of stomach appear normal 
 The continuity of mucosa was normal with no evidence of ulceration 
Liver 
 Increased sinusoidal space with vacuolated hepatocytes were observed 
occasionally 
 The cytoplasm of some cells shows rare empty vacuole-type spaces 
Kidney 
 Distinct tubular congestion were observed 
 Derangement in Interstitial connective tissue was observed 
Spleen 
 Marginal sinus (MS) of the rat and its sinus lining cells appears normal 
 Erythropoietic cells (EP) are scattered throughout the red pulp of both the 
samples. No abnormalities found in lymph node of both the samples 
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Uterus 
 Appearance of endometrium, myometrium and uterine glands was normal.  
 Endometrial gland, epithelium and blood vessels appears normal 
Ovary 
 Sequential arrangement of granulosa cells arounds oocyte was normal and regular 
 Follicular cells, cytoplasm and nucleus appears normal 
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Histopathology of Brain  
Low Power Magnification 10X 
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Histopathology of Heart  
Low Power Magnification 10X 
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Histopathology of Lung  
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Histopathology of Stomach  
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Histopathology of Liver  
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Histopathology of Kidney  
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Histopathology of Spleen  
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Histopathology of Testes  
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Histopathology Report 
 
Group ID: C1LMH 
Brain 
 Primary dendrites and glial cells appears normal 
 The CA zones of brain are filles with densely packed Pyramidal cells  
Heart 
o Appearance of cardiomyocyte was normal with dark nuclear region. The 
nuclei of muscle fibers appear oval arrangement 
Lung 
 No signs of airway secretion and bronchial secretion 
 Bronchial blood vessels and connective tissue appears normal with no sings of 
pulmonary edema 
Stomach 
 Lumina of blood vessels appears normal. Appearance of glandular lumen was 
normal 
 Intracytoplasmic zone of mucosa appears normal 
Spleen 
 Appearance of LF – lymphoid follicle; PALS – periarterial lymphoid sheath was 
normal with no significant signs of enlargement 
 No signs of immunological activities 
Liver 
 Liver parenchyma appears normal with no evidence of necrosis 
 Appearance of terminal hepatic venules (central veins) to the portal tracts was 
normal 
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Kidney 
 Some renal tubules and glomeruli appears hypertrophic  
 Interstitial connective tissue appears cohesive with distinct space in between 
 Proximal and distal convoluted tubule appears normal 
TESTES 
 Normal sertoli cell aligned properly on the basement membrane with oval dome 
shaped nucleus shows the normal morphology of the seminiferous tubule were 
observed 
 Appearance of leydig cells, interstitial tissue , seminiferous tubule, Sertoli cells 
and spermatogonia were normal 
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Histopathology of Brain  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Heart  
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Histopathology of Lung  
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Histopathology of Stomach  
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Histopathology of Liver  
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Histopathology of Kidney  
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Histopathology of Spleen  
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Histopathology of Uterus  
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Histopathology of Ovary  
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Histopathology Report 
 
Group ID: C1MFH 
Brain 
 Appearance of Hippocampal neurons was normal with dense network  
 No signs of ischemic changes in the cerebral hemisphere 
Heart 
 No evidence of necrotic myocardium 
 Appearance of fibrils and cross striations are equidistant 
Lung 
 Perivascular region appears normal, Alveolar septa and wall appeared widen and 
normal 
 No signs of lymphocyte cuffing 
Stomach 
 Lumina of blood vessels appears normal. Appearance of glandular lumen was 
normal 
 Intracytoplasmic zone of mucosa appears normal 
Spleen 
 No signs of perivascular inflammation 
 Appearance of splenic sinuses, Splenic cord and endothelial orientation was 
normal 
Liver 
 Appearance of terminal hepatic venules (central veins) to the portal tracts was 
normal 
 No signs of nodular degeneration and cirrhosis . 
 No evidence of collagen (fibrosis ) 
Kidney 
 Interstitial connective tissue appears cohesive with distinct space in between 
 Proximal and distal convoluted tubule appears normal 
Ovary 
 Appearance of antral follicle, primary oocyte and secondary follicles are normal 
Uterus 
 Arrangement of stratum basale, functionale and surface epithelium seems normal 
 Endometrial gland, epithelium and blood vessels appears normal 
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Histopathology of Brain in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
 
High Power Magnification 40X 
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Histopathology of Heart in Sub-acute toxicity Study 
Low Power Magnification 10X 
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Histopathology of Lung in Sub-acute toxicity Study 
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Histopathology of Stomach in Sub-acute toxicity Study 
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Histopathology of Liver in Sub-acute toxicity Study 
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Histopathology of Kidney in Sub-acute toxicity Study 
Low Power Magnification 10X 
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Histopathology of Spleen in Sub-acute toxicity Study 
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Histopathology of Uterus in Sub-acute toxicity Study 
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Histopathology of Testes in Sub-acute toxicity Study 
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Histopathology of Ovary in Sub-acute toxicity Study 
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Histopathology Report 
 
Group ID: C1MMH 
Brain 
o Arrangement of the neurons appears intact with no sings of degeneration 
or apoptotic changes in both the samples 
o Cortex region showed normal neurons with polygonal to round cell bodies 
containing dense cytoplasm. 
Heart 
o No evidence of collagen deposition in myocardium. 
o Appearance of myocyte was normal 
Lung 
 Lung parenchyma appears normal with regular arrangement of alveoli and 
alveolar sac with no signs of lymphocyte infiltration and pulmonary fibrosis 
Stomach 
 Regular arrangement of muscularisexterna and outer longitudinal muscle were 
observed 
 Regular histology of Inner circular muscle (ICM), gastric pit (GP), and muscularis 
mucosae (MM) were observed 
Spleen 
 Marginal sinus (MS) of the rat and its sinus lining cells appears normal 
 Presence of marginal at the interface of the red pulp with the PALS and follicles 
was observed 
Liver 
 Increased Sinusoidal space were observed 
 Cytoplasm appears normal with widen portal tract 
 The centrilobular hepatocytes appears normal with occasional cytoplasmic 
vacuolization 
 No evidence of mesenchymal reaction on to the hepatic parenchyma 
 Kidney 
 Derangement in Interstitial connective tissue was observed   
 Alteration in thickness of proximal convoluted tubule  
 Mild tubular degeneration with increase bowman‟s space 
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 Renal tubule with mild swollen epithelial cell 
 No signs of cellular necrosis  
TESTES 
 Normal sertoli cell aligned properly on the basement membrane with oval dome 
shaped nucleus shows the normal morphology of the seminiferous tubule were 
observed 
 Appearance of leydig cells, interstitial tissue , seminiferous tubule, Sertoli cells 
and spermatogonia were normal 
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Histopathology of Brain in Sub-acute toxicity Study 
Low Power Magnification 10X 
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Histopathology of Heart in Sub-acute toxicity Study 
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Histopathology of Lung in Sub-acute toxicity Study 
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Histopathology of Stomach in Sub-acute toxicity Study 
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Histopathology of Liver in Sub-acute toxicity Study 
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Histopathology of Kidney in Sub-acute toxicity Study 
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Histopathology of Spleen in Sub-acute toxicity Study 
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Histopathology of Uterus in Sub-acute toxicity Study 
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Histopathology of Ovary in Sub-acute toxicity Study 
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Histopathology Report 
 
Group ID:  Control Female 
Brain 
 No signs of pyknosis and perineural vacuolization 
 No signs of edema or degeneration were observed. 
 Arrangement of neurons on cerebral cortex appears normal and dense 
Heart 
o No evidence of collagen deposition in myocardium. 
o Appearance of myocyte was normal 
Lung 
 No signs of airway secretion and bronchial secretion 
 Bronchial blood vessels and connective tissue appears normal with no sings of 
pulmonary edema 
Stomach 
 No signs of ulcer and glandular degeneration were observed 
 Appearance of Sub-mucosa and gastric glands appear normal 
 
Liver 
 Hepatocyte appears with dark pigment chromatin in centri lobular and periportal 
region 
 Hepatic sinusoid and hepatic cord was normal 
 
Kidney 
 Glomerular cell integrity, basement membrane and nephrotic bundle appears 
normal 
 No signs of lesion or inflammation were observed 
 Proximal and distal convoluted tubule appears normal 
 
Spleen 
 Lymphoid follicles appears normal  
 Erythropoietic cells (EP) are scattered throughout the red pulp of both the 
samples. 
 
Uterus 
 Appearance of endometrium, myometrium and uterine glands was normal.  
 Endometrial gland, epithelium and blood vessels appears normal 
 
Ovary 
 Histopathological analysis of ovary showing normal corpus luteum (CL) and 
Primordial follicles with few mature ovarian follicles with no signs of 
abnormality. 
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Histopathology of Brain  
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Histopathology of Heart  
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Histopathology of Lung  
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Histopathology of Stomach  
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Histopathology of Liver  
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Histopathology of Kidney  
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Histopathology of Spleen  
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Histopathology of Testes  
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Histopathology Report 
 
Sample Id: Control Male 
Brain 
o Arrangement of the neurons appears intact with no signs of degeneration 
or apoptotic changes in both the samples 
o Cortex region showed normal neurons with polygonal to round cell bodies 
containing dense cytoplasm. 
Lung 
 Bronchial opening appears regular with no signs of infiltration 
 Appearance of alveolar network was normal 
 Nucleus of type I and II alveolar cells looks normal  
Heart 
o Perfectly -arranged myocardial fibers, clear transverse striation and normal 
structure were observed. 
o Appearance of cardiomyocyte was normal with dark nuclear region. The 
nuclei of muscle fibers appear oval arrangement 
Stomach 
 Gastric glands, gastric glands including secretary sheath appears normal 
 Normal gastric mucosa containing intact gastric gland cells, parietal cells which 
are spherical cell with deeply stained dark nucleus 
Spleen 
 No signs of perivascular inflammation 
 Appearance of splenic sinuses, Splenic cord and endothelial orientation was 
normal 
 Appearance of LF – lymphoid follicle; PALS – periarterial lymphoid sheath was 
normal with no significant signs of enlargement 
Liver 
 Rare appearance of Kupffer cells with no evidence of phagocytosis in 
intracytoplasmic region 
 Liver parenchyma appears normal with no evidence of necrosis 
 Appearance of terminal hepatic venules (central veins) to the portal tracts was 
normal 
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Kidney 
 Appearance of Podocytes and parietal epithelium in the glomeruli appears normal 
 Proximal and distal convoluted tubule appears normal 
 No signs of lesion or inflammation were observed 
 No signs of cellular necrosis  
Testes 
 Histo cytology of testicular tissue shows well differentiated germ cells with 
respect of spermatogonia includes spermatid and sperm were observed 
 Appearance of leydig cells, interstitial tissue, seminiferous tubule, Sertoli cells 
and spermatogonia were normal 
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OBSERVATION AND RESULTS 
 
The observation and results were studied and tabulated under the following heading. 
1) Sex distribution 
2) Age distribution 
3) Occupational status 
4) Family History 
5) Diet habits 
6) Thinai reference 
7) Kaalam distribution (According to Age) 
8) Kaalam distribution 
9) Yakkai Ilakkanam (Physical Constitution) 
10) Gunam reference 
11) Duration of illness 
12) Clinical features 
13) Distributions  of three thodams 
14) Udar Kattukkal reference 
15) En Vagaithervugal 
16) Neerkkuri reference 
17) Neikkuri reference 
18) SPADI SCORE 
19) Results 
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1. Sex distribution: 
 
S.no Sex distribution No of cases Percentage 
1. Male 18 45% 
2. Female 22 55% 
 
 
 
 
Observation: 
  Among the 40 patients selected for this study, 22(55%)were females and 
18(45%)were males. 
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2. Age distribution: 
 
S.no Age No of cases Percentage 
1. 20-35 - - 
2. 36-50 17 42.5% 
3. 51-65 23 57.5% 
 
 
 
Observation: 
 The patients were selected from all age groups as in inclusion criteria and the 
maximum numbers of patients (23) 57.5% were in the age between 51 and 65yrs and 
(17) 42.5% patients were in the age between 36 and50 years. 
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3. Occupational status: 
Sl. No Nature of Work No. of Cases Percentage 
1 Home Maker 18 45% 
2 Cooley 6 15% 
3 Driver 5 12.5% 
4 Businessman 2 5% 
5 Carpenter 3 7.5% 
6 Clerical 4         10% 
7 Baker 1 2.5% 
8 Electrician 1 2.5% 
 
 
 
 
 
 
Observation: 
 The majority of patients in this study were home maker &cooly 
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4. Family history: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observation: 
 100% of the patients showed negative family history. 
 
 
 
 
 
 
S.n 
S.no 
 
Family history 
No o 
No of cases 
Pe 
Percentage 
1. Family history (+ve) 0 - 0% - 
2. Family history (-ve) 404 40 100%100% 
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5. Dietary habits: 
 
S.no Dietary habits No of cases Percentage 
1. Vegetarian 2 5% 
2. Non-vegetarian 38 95% 
 
 
 
 
 
 
 
 
Observation: 
 95% of the patients were non-vegetarians. 
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6. Thinai distribution: 
 
S.no Thinai No of cases Percentage 
1. Kurinji - - 
2. Mullai - - 
3. Marutham 10 25% 
4. Neithal 30 75% 
5. Paalai -  - 
 
 
 
Observation: 
 75% of the patients were from Neithal(Coastal Area) and (25%) from Marutham 
(Fertile Land). 
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7. Kaalam distribution (According to age) 
In Siddha literature human life has been divided into three periods as follows 
1) Vatham(1-33yrs) 
2) Piththam(34-66yrs) 
3) Kabam(67-100yrs) 
The duration of each period is said to be 33 years 
 
S.no Kaalam No of cases Percentage 
1. Vaathakaalam(1-33yrs) - - 
2. Pithakaalam(34-66yrs) 40 100% 
3. Kabakaalam(67-100yrs) - - 
 
 
 
Observation: 
 100%of the patients were reported in Pithakaalam. 
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8. Kaalam distribution: 
 
S.no Kaalam distribution No of cases Percentage 
1. Kaarkaalam - - 
2. Koothirkaalam - - 
3. Munpanikaalam - - 
4. Pin panikaalam 40 100% 
5. Ilavenilkaalam - - 
6. Mudhuvenilkaalam - - 
 
 
 
 
Observation: 
 All the patients were admitted in Pinpanikaalam. 
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9. Yaakaiilakkanam(Physical constituents): 
 
S.no Yaakaiilakkanam No of cases Percentage 
1. Vaathaudal - - 
2. Pithaudal - - 
3. Kabaudal - - 
4. Thonthaudal 40 100% 
 
 
 
Observation: 
 All the patients (100%) had ThonthaUdal. 
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10. Gunam(Quality and Character) 
 
S.no Gunam No of cases Percentage 
1. Sathuvagunam - - 
2. Rasogunam 40 100% 
3. Thamogunam - - 
 
 
 
Observation: 
 All the patients (100%) had “RasoGunam”. 
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11. Duration of illness: 
 
S.no Duration of illness No of cases Percentage 
1. 0-3 months 23 57.5% 
2. 4-6months 
 
15 37.5% 
3. 7-9months 2 5% 
4. 10-12months - - 
5. >1yr - - 
 
 
 
Observation: 
 57.5% of the patients were suffering with the illness from 0-3 months,37.5% of 
patients suffering with the illness from 4-6 months,5% of cases suffering from 7-9 
months. 
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12. Clinical features: 
 
S.no Clinical features No of cases Percentage 
1. Pain  40 100% 
2. Restriction of movements in shoulder 40 100% 
3. Radiating pain in affected arm 40 100% 
4. Difficulty in abduction 40 100% 
5. Difficulty in external rotation 40 100% 
6. Tenderness  30 75% 
7. Local heat  7 17.5% 
 
 
 
Observation: 
 All patients in the study had clinical features of shoulder pain, restriction of 
movements, radiating pain in affected arm, Abduction, external rotation in100% of 
cases, 75% of cases had tenderness and 17.5% of cases have local heat. 
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13. Distribution of Mukkutram - Vaatham: 
 
S.no VaatVaatham No of                  no. 
of cases 
Perce         
Percentage 
1 Prana - - 
2 Abana 8 20% 
3 Uthan  3 7.5% 
4 Viyan  40 100% 
5 Sama  40 100% 
6 Nagan - - 
7 Koorman - - 
8 Kirugaran - - 
9 Devadathan 22 55% 
10 Dhananjayan - - 
 
 
 
Observation: 
 Samaanan and Viyaanan were affected in all the 40 patients. Abanan affected in 
20% of cases Devathaththan affected in 55% and uthanan affected in 7.5% of patients 
respectively. 
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Pitham: 
 
S.no PithaPitham No of No of cases Perce Percentage 
1. 
 
 
Anarpitham 
A 
- 
Nar 
- 
2. 
 
 
Ranjagapitham 
0 
- 
0% 
- 
3. 
 
 
Sathagapitham 
40 
40 
100% 
100% 
4. 
 
 
Pirasagapitham 
0 
- 
0% 
- 
5. 
 
 
Alosagapitham 
0 
- 
0% 
- 
 
 
 
 
Observation: 
 Saathagapitham is affected in all the cases. 
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Kabam: 
 
S.no 
S.no 
Kaba 
Kabam 
No of  No of cases Perc 
Percentage 
1. 
1 
Avalambagam 40 
40 
100% 
100% 
2. 
2 
Kilethagam 0 
- 
0% 
- 
3. 
3 
Pothagam 0 
- 
0% 
- 
4. 
4 
Tharpagam 0 
- 
0% 
- 
5. 
5 
Santhigam 40 
40 
 
100% 
 
 
 
 
Observation: 
 In Kabam Avalambagam and santhikam affected in all cases. 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
100%
0% 0% 0%
100%
KABAM
181 
 
14. Udarkattugal: 
 
S.no Udarkattugal No of cases Percentage 
1. Saaram 40 100% 
2. Senneer - - 
3. Oon 40 100% 
4. Kozhuppu - - 
5. Enbu - - 
6. Moolai - - 
7. Sukkilam/ Suronitham - - 
 
 
 
 
 
 
Observation: 
 Among 40 patients, Saaram and oonwere affected in all the cases.  
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15. Envagaithervugal: 
 
Sl. 
No 
EnvagaiThervugal No. of Cases Percentage 
1 Naadi 
 
 
Vathapiththam 29 72.5% 
Piththavatham 11 27.5% 
Kabavatham - - 
Kabapiththam - - 
2 Sparisam - - 
3 Naa - - 
4 Niram - - 
5 Mozhi - - 
6 Vizhi - - 
7 Malam 8 20% 
8 Moothiram - - 
 
 The Naadinadai seen in Kumbavaatham patients were Vathapitham(72.5%), 
Pithavatham(27.5 %). 
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16. Neerkuri Reference: 
S.no 
S.no 
Neerkuri No of    No of cases Perce  Percentage 
1. 
1 
Pale y Pale yellow 8 
8 
20% 
20% 
2. 
2 
Yello  Yellow 0 
- 
0% 
- 
3. 
3 
Dark   Dark yellow 2 
2 
5% 
5% 
4. 
4 
Straw  Straw colour 30 
30 
75% 
75% 
5. 
5 
Colou Colourless 0 
- 
0% 
- 
 
 
 
Observation: 
 In this study 50% of the patients had straw yellow, 20% with pale yellow,  
and5% with dark yellow . 
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17. Neikuri Reference: 
 
S.no Neikuri No of cases Percentage 
1. Vaatham(Aravenaneendathu) 23 57.5% 
2. Pitham(Aazhi pol paraviyathu) 7 17.5% 
3. Kabam(Muthothuninrathu) 3 7.5% 
4.      Others 7 17.5% 
 
 
 
Observation: 
 In this study 57.5% of the patients had Neikuri with Vatham (Aravana Neendal), 
17.5% with Piththam (Aazhipol Paraviyathu), 7.5% with Kabam (Muththothu ninrathu) 
and 17.5% with other pattern. 
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18 .SPADI SCORE (Pain scale) – With Varmam(Group A) 
 
S.N
O 
OP/IP 
NO 
NAME AGE/ 
SEX 
BT(%) AT (%) RESULT 
1 H40776 Mr.Dhandapani 62/M 74 22 GOOD 
2 9461 Mr.P.Babu 57/M 82 34 MODERATE 
3 I64222 Mrs.V.Mangai 43/F 72 18 GOOD 
4 8825 Mrs.Maheshwari 60/F 88 62 MODERATE 
5 I69664 Mr.T.M.Kumar 58/M 82 10 GOOD 
6 I03771 Mrs.Bakyamary 60/F 94 30 GOOD 
7 8858 Mrs.Indirani 50/F 90 10 VERY GOOD 
8 8859 Mrs.Vasanthi 64/F 86 14 GOOD 
9 I50208 Mr.P.V.sundarraj 54/M 72 16 GOOD 
10 I70853 Mr.Elamvazhuthi 61/M 78 18 GOOD 
11 H91187 Mr.Sugumar 37/M 92 30 GOOD 
12 G75398 Mrs.Maheshwari 50/F 84 8 VERY GOOD 
13 I61037 Mrs.Sumathi 50/F 76 10 GOOD 
14 I69442 Mrs.Mangayarthilagam 60/F 78 12 GOOD 
15 I88148 Mr.Iyyadurai 42/M 76 6 GOOD 
16 9557 Mrs.Thulasigam 55/F 82 14  GOOD 
17 I85923 Mr.Kandhasami 43/M 82 4  VERY GOOD 
18 I66909 Mr.Nagaraj 38/M 82 5 GOOD 
19 I70825 Mr.C.Nagarajan 60/M 90 48 MODERATE 
20 8909 Mrs.Meenatchi 57/F 92 4 VERY GOOD 
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SPADI SCORE (Disability scale) – With Varmam (Group A) 
 
S.NO 
 
OP/IP 
NO 
NAME AGE/ 
SEX 
BT(%) AT (%) RESULT 
1 H40776 Mr.Dhandapani 62/M 75 12.5 GOOD 
2 9461 Mr.P.Babu 57/M 82 23.75 GOOD 
3 I64222 Mrs.V.Mangai 43/F 64 15 GOOD 
4 8825 Mrs.Maheshwari 60/F 80 61.25 MILD 
5 I69664 Mr.T.M.Kumar 58/M 81.25 6.25 GOOD 
6 I03771 Mrs.Bakyamary 60/F 83.75 15 GOOD 
7 8858 Mrs.Indirani 50/F 80 13.75 GOOD 
8 8859 Mrs.Vasanthi 64/F 80 22.5 GOOD 
9 I50208 Mr.P.V.sundarraj 54/M 71.25 10 GOOD 
10 I70853 Mr.Elamvazhuthi 61/M 72.5 12.5 GOOD 
11 H91187 Mr.Sugumar 37/M 85 16.25 GOOD 
12 G75398 Mrs.Maheshwari 50/F 80 8.75 GOOD 
13 I61037 Mrs.Sumathi 50/F 71.25 6.25 GOOD 
14 I69442 Mrs.Mangayarthilag
am 
60/F 73.75 12.5 GOOD 
15 I88148 Mr.Iyyadurai 42/M 72.5 13.75 GOOD 
16 9557 Mrs.Thulasigam 55/F 77.5 6.25 GOOD 
17 I85923 Mr.Kandhasami 43/M 82.5 6.25 VERY GOOD 
18 I66909 Mr.Nagaraj 38/M 78.75 10 GOOD 
19 I70825 Mr.C.Nagarajan 60/M 82.5 48.75 MODERATE 
20 8909 Mrs.Meenatchi 57/F 87.5 8.75 VERY GOOD 
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SPADI SCORE (Total score) – With Varmam (Group A) 
 
S.N
O 
 
OP/IP 
NO 
NAME AGE/ 
SEX 
BT(%) AT (%) RESULT 
1 H40776 Mr.Dhandapani 62/M 74.61 15.96 GOOD 
2 9461 Mr.P.Babu 57/M 82.3 27.69 GOOD 
3 I64222 Mrs.V.Mangai 43/F 76.92 16.15 GOOD 
4 8825 Mrs.Maheshwari 60/F 83 61.5 MILD 
5 I69664 Mr.T.M.Kumar 58/M 81.53 7.69 GOOD 
6 I03771 Mrs.Bakyamary 60/F 87.69 20.76 GOOD 
7 8858 Mrs.Indirani 50/F 78.46 12.30 GOOD 
8 8859 Mrs.Vasanthi 64/F 82.30 19.23 GOOD 
9 I50208 Mr.P.V.Sundarraj 54/M 71.53 8.46 GOOD 
10 I70853 Mr.Elamvazhuthi 61/M 74.6 13.84 GOOD 
11 H91187 Mr.Sugumar 37/M 87.69 21.53 GOOD 
12 G75398 Mrs.Maheshwari 50/F 81.53 8.46 GOOD 
13 I61037 Mrs.Sumathi 50/F 73.07 7.69 GOOD 
14 I69442 Mrs.Mangayarthilagam 60/F 75.38 12.30 GOOD 
15 I88148 Mr.Iyyadurai 42/M 73.84 10.76 GOOD 
16 9557 Mrs.Thulasigam 55/F 79.23 9.23 GOOD 
17 I85923 Mr.Kandhasami 43/M 82.30 5.38 VERY GOOD 
18 I66909 Mr.Nagaraj 38/M 80 10 GOOD 
19 I70825 Mr.C.Nagarajan 60/M 85.38 48.46 GOOD 
20 8909 Mrs.Meenatchi 57/F 89.23 6.92 VERY GOOD 
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SPADI SCORE (Pain scale) - With Trial medicines (Group-B) 
S.NO OP/IP 
NO 
NAME AGE/ 
SEX 
BT(%) AT (%) RESULT 
1 C20391 Mr.K.Thirumaran 56/M 70 16 GOOD 
2 I41274 Mrs.M.Bhavani 40/F 70 14 GOOD 
3 I39463 Mrs.B.Jeeva 52/F 72 8 GOOD 
4 I37612 Mr.C.Mani 52/M 76 16 GOOD 
5 F043532 Mrs.Govinthammal 38/F 84 42 MODERATE 
6 H78671 Mrs.Nirmala 53/F 72 10 GOOD 
7 I24657 Mr.B.PareshBehera 55/M 88 46 MODERATE 
8 I68182 Mr.Rajasekaran 36/M 86 44 MODERATE 
9 G20673 Mrs.N.Meerabegam 45/F 72 22 MODERATE 
10 I69546 Mrs.Muthulakshmi 52/F 78 38 MODERATE 
11 H9339 Mrs.Selvakumari 58/F 80 30 GOOD 
12 F54907 Mr.Thangappan 59/M 78 16 GOOD 
13 I5160 Mrs.Muthukili 40/F 92 48 MODERATE 
14 G41863 Mrs.R.Kannagi 48/F 92 32 GOOD 
15 I31482 Mrs.R.K.Indrani 43/F 90 14 VERYGOOD 
16 I48564 Mr.P.Sokkuvel 62/M 92 17 GOOD 
17 H37544 Mr.D.Kalavathy 64/M 74 32 MODRATE 
18 I72321 Mr.K.Kumar 42/M 84 42 MODERATE 
19 H63909 Mrs.B.Srimathi 42/F 94 4 MODERATE 
20 I7770 Mrs.Amsavani 63/F 82 22 GOOD 
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SPADI SCORE (Disability scale) - With Trial medicines (Group-B) 
S.NO OP/IP 
NO 
NAME AGE/ 
SEX 
BT(%) AT (%) RESULT 
1 C20391 Mr.K.Thirumaran 56/M 71.25 15 GOOD 
2 I41274 Mrs.M.Bhavani 40/F 67.5 13.75 GOOD 
3 I39463 Mrs.B.Jeeva 52/F 70 11.25 GOOD 
4 I37612 Mr.C.Mani 52/M 81.25 32.5 MODERATE 
5 F043532 Mrs.Govinthammal 38/F 77.5 37.5 MODERATE 
6 H78671 Mrs.Nirmala 53/F 83.75 23.75 GOOD 
7 I24657 Mr.B.PareshBehera 55/M 82.5 37.5 MODERATE 
8 I68182 Mr.Rajasekaran 36/M 86.25 27.5 GOOD 
9 G20673 Mrs.N.Meerabegam 45/F 85 26.25 GOOD 
10 I69546 Mrs.Muthulakshmi 52/F 68.75 33.75 MODERATE 
11 H9339 Mrs.Selvakumari 58/F 78.75 27.5 MODERATE 
12 F54907 Mr.Thangappan 59/M 81.25 20 GOOD 
13 I5160 Mrs.Muthukili 40/F 85 46.25 MODERATE 
14 G41863 Mrs.R.Kannagi 48/F 82.5 42.5 MODERATE 
15 I31482 Mrs.R.K.Indrani 43/F 85 16.25 GOOD 
16 I48564 Mr.P.Sokkuvel 62/M 80 37.5 MODERATE 
17 H37544 Mr.D.Kalavathy 64/M 80 36.25 MODRATE 
18 I72321 Mr.K.Kumar 42/M 77.5 37.5 MODERATE 
19 H63909 Mrs.B.Srimathi 42/F 87.5 11.5 VERY GOOD 
20 I7770 Mrs.Amsavani 63/F 81.25 28.75 GOOD 
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SPADI SCORE (Total) - With Trial medicines (Group-B) 
 
S.NO OP/IP 
NO 
NAME AGE/ 
SEX 
BT(%) AT (%) RESULT 
1 C20391 Mr.K.Thirumaran 56/M 70.76 15.38 GOOD 
2 I41274 Mrs.M.Bhavani 40/F 68.46 13.84 GOOD 
3 I39463 Mrs.B.Jeeva 52/F 70 10 GOOD 
4 I37612 Mr.C.Mani 52/M 79.25 26.15 GOOD 
5 F043532 Mrs.Govinthammal 38/F 80 39.23 MODERATE 
6 H78671 Mrs.Nirmala 53/F 79.23 18.46 GOOD 
7 I24657 Mr.B.PareshBehera 55/M 84.61 40.76 MODERATE 
8 I68182 Mr.Rajasekaran 36/M 86.15 33.84 GOOD 
9 G20673 Mrs.N.Meerabegam 45/F 80 24.61 GOOD 
10 I69546 Mrs.Muthulakshmi 52/F 72.30 50 MILD 
11 H9339 Mrs.Selvakumari 58/F 78.87 26.15 GOOD 
12 F54907 Mr.Thangappan 59/M 80 18.46 GOOD 
13 I5160 Mrs.Muthukili 40/F 80 46.92 MODERATE 
14 G41863 Mrs.R.Kannagi 48/F 86.1 38.4 MODERATE 
15 I31482 Mrs.R.K.Indrani 43/F 86.92 15.38 GOOD 
16 I48564 Mr.P.Sokkuvel 62/M 84.61 36.1 MODERATE 
17 H37544 Mr.D.Kalavathy 64/M 77.69 34.61 MODERATE 
18 I72321 Mr.K.Kumar 42/M 80 39.23 MODERATE 
19 H63909 Mrs.B.Srimathi 42/F 90 8.46 VERY GOOD 
20 I7770 Mrs.Amsavani 63/F 81.53 26.15 GOOD 
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18. PROGNOSIS(WITH VARMAM and WITHOUT VARMAM): 
 
Prognosis 
 
            Total score 
 Without varmam 
No of 
patients 
Percentage No of 
patients 
Percentage 
Mild 1 5% 1 5% 
Moderate - - 7 35% 
Good 17 85% 11 55% 
Very good 2 10% 1 5% 
 
 
 
 
Observation: 
 In this study, Very Good improvement were observed in 10% of cases with 
varmam and 5% of cases without varmam group, Good improvement were observed in 
85% of cases with varmam and 55% of caseswithout varmam, Moderate improvement 
observed in 35% of cases without varmam group and  5% of cases in both the groups 
shows Mild improvement. 
Mild Moderate Good Very good
5%
0%
85%
10%
5%
35%
55%
5%
PROGNOSIS
With varmam Without varmam
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Results 
 The trial drug Rajaelathychooranam(Internal) and Nathaichooriennai (External) 
were given to 40 patients for 48 days. 
 
 
Observation: 
 The trial drug Rajaelathychooranam(Internal) and Nathaichooriennai (External) 
were given to 40 patients for 48 days. Very Good improvement was observed in 3 
patients (7.5%), Good improvement was observed in 28 patients (70%), moderate 
improvement in 7 patients (17.5%), and mild improvement in 2 (5%) cases.  
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Sl. No Results No of Cases Percentage 
1 Very Good 3 7.5% 
2 Good 28 70% 
3 Moderate 7 17.5% 
 4            Mild 2 5% 
193 
 
Deference between Varmam and Withoutvarmam Group: 
 
S 
Group 
 
Sample size 
 
Mean 
 
Standard 
deviation 
 
Significant 
 
Varmam 
 
20 
 
17.215 
 
14.296 
 
0.0063 
 
Without 
varmam 
 
20 
 
28.1065 
 
12.433 
 
0.10 
 
There was differences in with varmam and without varmam group after treatment. 
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S 
NO 
OP NO NAME 
AGE/ 
SEX 
Hb 
Total     
RBC 
ESR 
Total WBC 
½ hour 1hour 
 BT AT BT AT BT AT BT AT BT AT 
1 H40776 MR.Dhandapani 62/M 15.6 14.8 4.5 5.0 20 20 40 40 7900 6800 
2 9461 Mr.P.Babu 57/M 13.5 14 4.8 4.2 25 25 42 40 7000 7200 
3 I64222 Mr.V.Mangai 43/F 13.7 13.6 4.5 4.5 8 8 16 16 7600 6300 
4 8825 MMaheshwari 60/F 12.0 12.7 4.1 4.3 10 8 20 16 6400 6300 
5 I69664 T.M.Kumar 58/M 14.6 14.9 5.1 5.2 10 10 20 20 6100 5800 
6 I03771 Bakyamary 60/F 14.6 15 4.7 4.7 34 12 17 24 7500 7600 
7 I80615 Indirani 50/F 13 13.5 4.5 4.6 15 10 30 31 7100 7000 
8 8859 Vasanthi 64/F 11.1 11.9 3.9 4.2 24 34 48 70 9400 8300 
9 I50208 P.V.sundarraj 54/M 12 13 4.3 4.4 25 28 30 30 8000 8100 
10 I70853 Elamvazhuthi 61/M 14.8 15 5.2 5.2 2 2 4 4 6200 6400 
11 H91187 Sugumar 37/M 15.7 15.5 5.2 5.2 2 2 4 4 6200 6400 
12 G75398 Maheshwari 50/F 12.7 12.3 4.7 4.2 10 10 20 20 7700 7500 
13 I61037 Sumathi 50/F 12.8 13 4.5 4.5 10 10 20 20 5500 5600 
14 I69442 Mangayarthilagam 60/F 12.6 13 4.7 4.5 8 8 16 16 7200 7300 
15 I88148 Iyyadurai 42/M 14.7 15.7 5.0 5.5 4 4 10 10 13000 11000 
16 9557 Thulasigam 55/F 14 14.5 4.3 5.3 4 4 8 8 4000 5000 
17 I85923 Kandhasami 43/M 14.6 15 5.8 5 6 6 14 14 10000 10000 
18 I66909 Nagaraj 38/M 16.1 16 5.7 5.5 2 2 4 4 7800 7600 
19 I70825 C.Nagarajan 60/M 14.5 15.1 5.1 5.3 4 14 10 30 8800 7400 
20 8909 Meenatchi 57/F 12.9 13 4.9 4.5 10 10 22 22 10900 10000 
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S.NO OP NO NAME 
AGE/ 
SEX 
SGOT SGPT 
ALKALINE 
PHOPHAT
ASE 
BT AT BT AT BT AT 
1 C20391 K.Thirumaran 56/M 23 17 16 14 82 54 
2 I41274 M.Bhavani 40/F 14 17.5 17 14.8 70 67 
3 I39463 B.Jeeva 52/F 19 21 64 16 62 64 
4 I37612 C.Mani 52/M 17 23 15 24 56 60 
5 F043532 Govinthammal 38/F 15 17 21 21 105 105 
6 H78671 Nirmala 53/F 17 18 17 14 72 74 
7 I24657 B.PareshBehera 55/M 24 25 30 30 63 41 
8 I68182 Rajasekar 36/M 17 20 29 25 69 69 
9 G20673 N.Meerabegam 45/F 22 25.1 24 25.1 79 77 
10 I69546 Muthulakshmi 52/F 13 19 13 10 74 78 
11 H9339 Selvakumari 58/F 22 10.3 23 21 97 89 
12 F54907 Thagappan 59/M 23 21 21 15 71 70 
13 I5160 MUTHUKILI 40/F 13 22.5 19 20.5 69 78 
14 G41863 R.Kannagi 48/F 15 15 19 20 99 100 
15 I31482 R.K.Indrani 43/F 19 16 19 11 42 102 
16 I48564 P.Sokkuvel 62/M 69 13 12 10 70 56 
17 H37544 D.Kalavathy 64/M 15 17 13 16 77 87 
18 I72321 K.Kumar 42/M 19 20 20 25 76 70 
19 H63909 B.Srimathi 42/F 16.0 16.3 16.3 16.3 68 69 
20 I7770 Amsavani 63/F 15 14 13 18 98 101 
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S. 
No 
 
OP No 
 
 
NAME 
AGE/ 
SEX 
 
URINE 
SUGER 
(F) 
URINE 
SUGER 
(PP) 
ALBUMIN 
Epithelial 
cell 
Pus cells 
     BT AT BT AT BT AT BT AT BT AT 
1 C20391 K.Thirumaran 56/M nil nil nil Nil nil nil 2-4 2-4 6-7 2-3 
2 I41274 M.Bhavani 40/F nil nil nil Nil nil nil 2-4 3-5 2-4 3-5 
3 I39463 B.Jeeva 52/F nil nil nil Nil nil nil 2-3 2-3 1-2 1-2 
4 I37612 C.Mani 52/M nil nil nil Nil nil nil 2-4 2-4 2-3 3-3 
5 F043532 Govinthammal 38/F nil nil nil Nil nil nil 6-7 3-4 2-4 1-2 
6 H78671 Nirmala 53/F nil nil nil Nil nil nil 2-3 1-2 2-3 2-3 
7 I24657 B.PareshBehera 55/M nil nil nil Nil nil nil 2-3 2-3 1-2 2-4 
8 I68182 Rajasekar 36/M nil nil nil Nil nil nil 1-2 2-4 1-2 2-4 
9 G20673 N.Meerabegam 45/F nil nil nil Nil nil nil 2-3 2-3 2-3 1-2 
10 I69546 Muthulakshmi 52/F nil nil nil Nil nil nil 4-5 3-5 1-2 1-2 
11 H9339 Selvakumari 58/F nil nil nil Nil nil nil 10-12 2-3 4-5 2-4 
12 F54907 Thagappan 59/M nil nil nil Nil nil nil 2-4 3-5 2-3 2-3 
13 I5160 MUTHUKILI 40/F nil nil nil Nil nil nil 1-2 1-2 6-8 1-2 
14 G41863 R.Kannagi 48/F nil nil nil Nil nil nil 2-4 2-4 1-3 1-3 
15 I31482 R.K.Indrani 43/F nil nil nil Nil nil nil 2-4 1-2 2-4 1-2 
16 I48564 P.Sokkuvel 62/M nil nil nil Nil nil nil 2-4 6-7 4-6 2-3 
17 H37544 D.Kalavathy 64/M nil nil nil Nil nil nil 3-5 2-5 2-4 2-4 
18 I72321 K.Kumar 42/M nil nil nil Nil nil nil 1-2 1-2 2-4 1-2 
19 H63909 B.Srimathi 42/F nil nil nil Nil nil nil 3-5 2-5 1-4 1-2 
20 I7770 Amsavani 63/F nil nil nil Nil nil nil 3-5 2-5 1-4 1-2 
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S 
No 
Op No Name Age/ 
Sex 
Blood 
Glucose 
(F) 
Blood 
Glucose 
Urea Creatinnine Total 
Cholesteral 
 
BT AT BT AT BT AT BT AT BT AT 
1 H40776 Thandapani 62/M 107 102 109 110 22 21 1.0 0.9 195 188 
2 9461 P.Babu 57/M 99 94 106 115 12 13 1.1 1.0 156 158 
3 I64222 V.Mangai 43/F 110 108 113 110 16 14 0.8 0.8 179 140 
4 8825 Maheshwari 60/F 97 98.8 109 110 24.8 20.7 0.99 0.87 160 169 
5 I69664 T.M.Kumar 58/M 107 102 150 158 14 13 1.1 1.0 200 194 
6 I03771 Bakyamary 60/F 102 100 103 130 13 13 1.0 1.0 178 178 
7 I80615 Indirani 50/F 104 115 124 120 16 15 1.1 1.2 181 168 
8 8859 Vasanthi 64/F 109 110 139 135 15 14 1.0 0.8 197 200 
9 I50208 P.V.sundarraj 54/M 96 106 140 116 14 16 0.9 1.1 165 165 
10 I70853 Elamvazhuthi 61/M 99 100 120 120 21 28 1.0 1.0 168 170 
11 H91187 Sugumar 37/M 84 90 94 100 15 16 0.9 0.8 152 153 
12 G75398 Maheshwari 50/F 110 109 125 120 19 19 1.0 0.9 251 256 
13 I61037 Sumathi 50/F 93 90 101 120 28 20 1.2 1.0 208 200 
14 I69442 Mangayar 
thilagam 
60/F 98 100 120 125 17 18 0.8 1.0 183 170 
15 I88148 Iyyadurai 42/M 95 94 135 145 26 17 1.2 1.0 231 175 
16 9557 Thulasigam 55/F 89.9 89.9 110 120 29.8 30 1.09 1.0 168 170 
17 I85923 Kandhasami 43/M 98 100 106 107 26 26 1.1 1.1 189 190 
18 I66909 Nagaraj 38/M 87 90 133 129 32 32 1.0 1.0 230 212 
19 I70825 C.Nagarajan 60/M 99 100 135 139 34 19 1.0 0.9 181 189 
20 8909 Meenatchi 57/F 116 110 140 140 24.1 24 0.99 1 189 190 
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S 
NO 
OP NO NAME AGE
/ 
SEX 
Total 
bilirubin 
calcium Phosphorus Uric acid 
BT AT BT  AT BT AT BT AT 
1 H40776 Thandapani 62/M 0.7 0.5 8.9 8.2 3.6 3.4 4.4 4.8 
2 9461 P.Babu 57/M 1.1 0.4 8.4 9.1 3.2 3.4 6.2 6.1 
3 I64222 V.Mangai 43/F 0.3 0.3 9.1 9.0 2.7 3.3 3.7 3.7 
4 8825 Maheshwari 60/F 1.2 1.2 8.4 9.0 3.95 4.54 4.5 4.2 
5 I69664 T.M.Kumar 58/M 2.0 0.6 9.0 8.4 3.4 3.5 5.8 5.3 
6 I03771 Bakyamary 60/F 0.7 0.7 9.2 9.3 3.6 3.7 4.7 4.8 
7 I80615 Indirani 50/F 0.5 0.6 9.0 9.2 3.2 3.3 4.3 4.5 
8 8859 Vasanthi 64/F 0.4 0.7 8.4 8.4 2.7 3.3 5.2 4.9 
9 I50208 P.V.sundarraj 54/M 1.1 1.3 9.3 9.2 3.1 3.0 4.1 4.2 
10 I70853 Elamvazhuthi 61/M 1.2 1.2 8.4 9.0 2.3 2.5 6.7 7 
11 H91187 Sugumar 37/M 2.2 2.2 8.1 8.2 2.8 2.8 5.2 5.3 
12 G75398 Maheshwari 50/F 0.5 0.4 9.2 9.1 3.4 3.9 6.1 5.8 
13 I61037 Sumathi 50/F 0.5 0.6 9.2 9.3 4.3 4.3 5.6 5.5 
14 I69442 Mangayarthilagam 60/F 0.4 0.4 9.5 9.6 3.0 3.0 3.0 3.2 
15 I88148 Iyyadurai 42/M 0.3 0.4 9.7 8.6 3.8 3.7 9.0 8.4 
16 9557 Thulasigam 55/F 0.8 0.8 9.5 10 3.21 3.2 6.3 6.4 
17 I85923 Kandhasami 43/M 0.3 0.3 9.1 9.2 3.3 3.3 6.6 7 
18 I66909 Nagaraj 38/M 0.4 0.4 9.1 9.3 3.2 3.4 5.0 5.0 
19 I70825 C.Nagarajan 60/M 0.5 0.3 9.6 9.6 2.8 2.7 5.7 5.6 
20 8909 Meenatchi 57/F 1.15 1.1 9.1 9 3.17 4 5.0 4.5 
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S 
NO 
OP NO NAME AGE/ 
SEX 
urine Urine Albumin Epithelial 
cell 
Pus cells 
 BT AT BT  AT BT AT BT AT BT at 
1 H40776 Thandapani 62/M nil nil nil nil nil Nil 4-5 3-5 1-2 1-2 
2 9461 P.Babu 57/M nil nil nil nil nil Nil 10-12 2-3 4-5 2-4 
3 I64222 V.Mangai 43/F nil nil nil nil nil Nil 2-4 3-5 2-3 2-3 
4 8825 Maheshwari 60/F nil nil nil nil nil Nil 1-2 1-2 6-8 1-2 
5 I69664 T.M.Kumar 58/M nil nil nil nil nil Nil 2-4 2-4 1-3 1-3 
6 I03771 Bakyamary 60/F nil nil nil nil nil Nil 2-4 1-2 2-4 1-2 
7 I80615 Indirani 50/F nil nil nil nil nil Nil 2-4 2-4 6-7 2-3 
8 8859 Vasanthi 64/F nil nil nil nil nil Nil 2-4 3-5 2-4 3-5 
9 I50208 P.V.sundarraj 54/M nil nil nil nil nil Nil 2-3 2-3 1-2 1-2 
10 I70853 Elamvazhuthi 61/M nil nil nil nil nil Nil 2-4 2-4 2-3 3-3 
11 H91187 Sugumar 37/M nil nil nil nil nil Nil 6-7 3-4 2-4 1-2 
12 G75398 Maheshwari 50/F nil nil nil nil nil nil 2-3 1-2 2-3 2-3 
13 I61037 Sumathi 50/F nil nil nil nil nil nil 2-3 2-3 1-2 2-4 
14 I69442 Mangayarthilagam 60/F nil nil nil nil nil nil 1-2 2-4 1-2 2-4 
15 I88148 Iyyadurai 42/M nil nil nil nil nil nil 2-3 2-3 2-3 1-2 
16 9557 Thulasigam 55/F nil nil nil nil nil nil 4-5 3-5 1-2 1-2 
17 I85923 Kandhasami 43/M nil nil nil nil nil nil 10-12 2-3 4-5 2-4 
18 I66909 Nagaraj 38/M nil nil nil nil nil nil 2-4 3-5 2-3 2-3 
19 I70825 C.Nagarajan 60/M nil nil nil nil nil nil 1-2 1-2 6-8 1-2 
20 8909 Meenatchi 57/F nil nil nil nil nil nil 1-2 2-4 1-2 2-4 
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S.NO 
 
IP OP 
No 
NAME AGE/ 
SEX 
Hb(gm/dl) TOTAL RBC 
COUNT 
(million/cumm) 
ESR 
(mm/hour) 
TOTAL 
WBC 
COUNT 
BT AT BT AT BT AT AT AT BT AT 
1 C20391 K.Thirumaran 56/M 15 14 5.6 5.2 2  4 2 4 5600 5800 
2 I41274 M.Bhavani 40/F 11.5 11.5 4.7 4.9 22 46 15 30 8000 8200 
3 I39463 B.Jeeva 52/F 13.9 13.`1 4.5 4.2 2 4 2 4 9400 9900 
4 I37612 C.Mani 52/M 14.1 14.1 4.8 4.8 6 14 4 8 6100 6000 
5 F043532 Govinthammal 38/F 9.9 10.3 4.1 4.1 12 24 20 42 10400 10600 
6 H78671 Nirmala 53/F 12.6 12.8 4.5 4.7 12 26 20 42 5500 6700 
7 I24657 B.PareshBehera 55/M 12 12.5 4.5 5.4 8 16 8 16 7400 8600 
8 I68182 Rajasekar 36/M 15.3 15.1 5.7 5.6 8 16 8 16 6900 8100 
9 G20673 N.Meerabegam 45/F 12.8 13 4.5 4.5 12 26 20 42 6400 6600 
10 I69546 Muthulakshmi 52/F 14.5 14.5 5.1 5.1 12 24 20 42 7700 6100 
11 H9339 Selvakumari 58/F 14.5 12 4.1 4.2 30 60 30 60 8900 9000 
12 F54907 Thagappan 59/M 13.9 14 4.7 4.7 8 16 8 16 7300 8000 
13 I5160 Muthukili 40/F 11.6 11.5 4.5 4.4 4 8 4 8 7300 5700 
14 G41863 R.Kannagi 48/F 11.9 11.7 4.5 4.4 20 46 16 34 4400 5200 
15 I31482 R.K.Indrani 43/F 10.2 10.3 4.3 4.2 16 32 56 112 4200 5300 
16 I48564 P.Sokkuvel 62/M 14.5 14 5 4.8 20 44 10 20 8700 8700 
17 H37544 D.Kalavathy 64/M 14.8 14.7 5.3 5.3 8 16 16 16 6600 6000 
18 I72321 K.Kumar 42/M 14.5 12 4.1 4.2 30 60 30 60 8900 9000 
19 H63909 B.Srimathi 42/F 13.2 13 4.3 4.5 6 12 6 12 7600 7000 
20 I7770 Amsavani 63/F 13.3 13 4.4 4.3 8 16 8 16 6100 6100 
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S.NO IP/OP 
NO 
NAME AGE/ 
SEX 
ASO CRP RA FACTOR 
BT AT BT AT BT AT 
1 H40776 MR.Dhandapani 62/M - - - - - - 
2 9461 Mr.P.Babu 57/M - - - - - - 
3 I64222 Mr.V.Mangai 43/F - - - - - - 
4 8825 MMaheshwari 60/F - - - - - - 
5 I69664 T.M.Kumar 58/M - - + + - - 
6 I03771 Bakyamary 60/F - - + + - - 
7 I80615 Indirani 50/F - - + + - - 
8 8859 Vasanthi 64/F - - - - - - 
9 I50208 P.V.sundarraj 54/M - - - - - - 
10 I70853 Elamvazhuthi 61/M - - - - - - 
11 H91187 Sugumar 37/M - - - - - - 
12 G75398 Maheshwari 50/F - - + + - - 
13 I61037 Sumathi 50/F - - + + - - 
14 I69442 Mangayarthilagam 60/F - - + + - - 
15 I88148 Iyyadurai 42/M - - - - - - 
16 9557 Thulasigam 55/F - - - - - - 
17 I85923 Kandhasami 43/M - - - - - - 
18 I66909 Nagaraj 38/M - - - - - - 
19 I70825 C.Nagarajan 60/M - - - - - - 
20 8909 Meenatchi 57/F - - - - - - 
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S.NO IP/OP 
NO 
NAME AGE/ 
SEX 
ASO CRP RAFACTOR 
BT AT BT AT BT AT 
2 I41274 M.Bhavani 40/F - - - - - - 
3 I39463 B.Jeeva 52/F - - - - - - 
4 I37612 C.Mani 52/M - - - - - - 
5 F043532 Govinthammal 38/F - - - - - - 
6 H78671 Nirmala 53/F - - - - - - 
7 I24657 B.PareshBehera 55/M - - + + - - 
8 I68182 Rajasekar 36/M - - + + - - 
9 G20673 N.Meerabegam 45/F - - +  - - 
10 I69546 Muthulakshmi 52/F - - - - - - 
11 H9339 Selvakumari 58/F - - - - - - 
12 F54907 Thagappan 59/M - - - - - - 
13 I5160 MUTHUKILI 40/F - - - - - - 
14 G41863 R.Kannagi 48/F - - + + - - 
15 I31482 R.K.Indrani 43/F - - + + - - 
16 I48564 P.Sokkuvel 62/M - - + + - - 
17 H37544 D.Kalavathy 64/M - - + + - - 
18 I72321 K.Kumar 42/M - - - - - - 
19 H63909 B.Srimathi 42/F - - - - - - 
20 I7770 Amsavani 63/F - - - - - - 
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S.NO OP NO NAME 
AGE/ 
SEX 
SGOT SGPT 
ALKALINE 
PHOPHAT
ASE 
BT AT BT AT BT AT 
1 H40776 MR.Dhandapani 62/M 23 17 16 14 82 54 
2 9461 Mr.P.Babu 57/M 14 17.5 17 14.8 70 67 
3 I64222 Mr.V.Mangai 43/F 19 21 64 16 62 64 
4 8825 MMaheshwari 60/F 17 23 15 24 56 60 
5 I69664 T.M.Kumar 58/M 15 17 21 21 105 105 
6 I03771 Bakyamary 60/F 17 18 17 14 72 74 
7 I80615 Indirani 50/F 24 25 30 30 63 41 
8 8859 Vasanthi 64/F 17 20 29 25 69 69 
9 I50208 P.V.sundarraj 54/M 22 25.1 24 25.1 79 77 
10 I70853 Elamvazhuthi 61/M 13 19 13 10 74 78 
11 H91187 Sugumar 37/M 22 10.3 23 21 97 89 
12 G75398 Maheshwari 50/F 23 21 21 15 71 70 
13 I61037 Sumathi 50/F 13 22.5 19 20.5 69 78 
14 I69442 Mangayarthilagam 60/F 15 15 19 20 99 100 
15 I88148 Iyyadurai 42/M 19 16 19 11 42 102 
16 9557 Thulasigam 55/F 69 13 12 10 70 56 
17 I85923 Kandhasami 43/M 15 17 13 16 77 87 
18 I66909 Nagaraj 38/M 19 20 20 25 76 70 
19 I70825 C.Nagarajan 60/M 16.0 16.3 16.3 16.3 68 69 
20 8909 Meenatchi 57/F 15 14 13 18 98 101 
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STATISTICAL ANALYSIS 
 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. 
Basic descriptive statistics include frequency distributions and cross-tabulations were 
performed. The quantity variables were expressed as Mean ± Standard Deviation and 
qualitative data as percentage. A probability value of <0.05 was considered to indicate as 
statistical significance. Paired„t‟ test was performed for determining the significance 
between before and after treatment.  
 
Paired Sample Statistics (SPADI) Score Before Treatment and After Treatment 
for Group A (Trial medicine along with Varmam) 
 
Variable Obs Mean±SD t Value p Value 
Before treatment 20 80.0295±5.189 
T=20.921 p>0.0063 
After treatment 20 
   
17.215±14.296 
 
The mean± standard deviation of SPADI score before and after treatment were 
80.0295 ±5.189 and 17.215 ±14.296 respectively which is statistically significant 
(t=20.921, p=0.0063).  
 
Paired Sample Statistics (SPADI) Score Before Treatment and After Treatment 
                                    For Group B (Trial medicine only)    
Variable Obs Mean±SD t Value p Value 
Before treatment 20 79.824±5.861 
T=17.831 p>0.10 
After treatment     20   28.1065±12.433 
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The mean± standard deviation of SPADI score at before and after treatment were 
79.824 ±5.861and 28.1065±12.433respectively. (t=17.831, p=0.10).  
 
Difference between group –A and group - B 
Sco Score Sample size Mean Standard deviation Significant 
Group -A         20 17.215 5.189 0.0063 
AAA   
Group - B 
20 28.1065 12.433 0.10 
 
The result of group A (with varmam) is significant than the group B ( without Varma) 
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DISCUSSION 
 Periarthritis (Kumbavatham) is one of the Painfull and Disabiling disorders of 
unclear cause in shoulder capsule the connective tissue surrounding the glenohumeral 
joint of the shoulder. People who suffer from periarthritis usually experience severe pain 
and sleep disturbances, they have extreme difficulty concentrating, working or 
performing daily activities for extend period of time. The condition tends to be self 
limiting and usually resolves over time without surgery. 
 The trial drugs were prepared in Gunapadam lab of National Institute of Siddha 
after the authentication of the raw drugs from Dr. D. Aravind M.D(S) Assistant 
professor, Dept. of Botany, National institute of siddha.  The trail drug was prepared by 
standard operating procedure as mentioned in the Protocol. 
 
 The Bio chemical analysis was done at the biochemistry lab of NIS and the 
results were documented. The Bio-chemical analysis of had shown the presence of 
Chloride, Phosphate, Carbonate, Calcium, Potassium, Nitrite, Iron, Tannic acid, starch, 
sulphate and Alkaloids. 
 
The short term toxicity study in animal models carried out as per WHO guideline, 
there was no treatment- related death or signs of toxicity developed in albino rats at 
dosage levels of 2000mg / kg body weight throughout the study period. Further, no gross 
pathological changes have been seen in the internal organs of both control and treated 
groups. Thus, the LD50 value was found to be greater than 2000mg / kg body weight, and 
this provides direct relevance for protecting human and animal health. 
To ensure the safety of Rajaelathy Chooranam, Long  term Toxicity Study was 
also carried out as per WHO guideline, except for hyperactivity at the time of drug 
administration, no other signs of toxicity were noted. After blood collection, all the 
animals were euthanized for gross pathological examinations of all major internal organs. 
The blood samples were sent to a lab for hematological and biochemical analysis. The 
organs were weighed and preserved in 10% buffered formalin solution before sending for 
histopathological study. All the reports were statistically analyzed. 
 There was no Significant changes in food intake of the test group animals before 
and after the administration of trial drug when compared with control group during the 
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study period. The haemopoietic system serves as an important target for toxic chemicals 
and is a sensitive index for pathological conditions both in humans and animals. In 
Haematological parameters, it had been observed normal in high dose level, 
Transaminases (SGOT and SGPT) are good indicators of liver function and biomarkers to 
predict the possible toxicity of drugs. Any elevation pertaining to the enzymes indicate 
their out flow in to the blood stream due to damage in liver parenchymal cells, there was 
normal limits in SGOT and SGPT in high dose treated animals, when compared to control 
group.  In the present study, there was no treatment-related abnormality in renal functions 
at all the animals.  The therapeutic dose of Rajaelathy Chooranam is 2gm/day for the 
human uses mentioned in Siddha text. This dose was safest dose in humans form the above 
studies.  
In histopathologicalstudy, organs such as brain, heart, kidney, liver, lungs, spleen 
and stomach were taken. In organs of Control group, no abnormality was detected during 
the study period. 
 The Literature Review reveals that there was no such research has been done on 
Rajaelathy Chooranam. As an initial step, in this present study, a part of 
standardization of this drug and its safety has been confirmed through necessary analysis 
and Short term & Long term Toxicity studies as per WHO guidelines. 
 
 The clinical study was conducted with a well-defined protocol and a proper 
proforma after the approval of Institutional Ethical Committee. 
 
 For this dissertation study, 40 patients were selected and Patients were treated in 
the OP/IP department of Sirappu Maruthuvam, in Ayothidoss Pandithar Hospital - 
National Institute of  Siddha, Tambaram Sanatorium, Chennai –600 047. 
 
 Based on various criteria, the data were collected and tabulated. The criteria 
were family history, sex predominance, age distribution, occupation, dietary habits and 
incidence of the disease with reference to thinai, seasonal variation, clinical 
manifestations and assessment of the improvement in the prognosis of the disease with 
the trial drug. 
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 In Siddha System, it is necessary to bring the vitiated humours to equilibrium. 
Hence before the treatment Meganatha kuzhigai-2 pills with warm water was given for 
Viresanam  (Purgation) in the early morning to normalize the vitiated humours. During 
the treatment, the patients were advised to follow pathiyam (Dietary regimen). 
 
Internal Drug          : Rajaelathy chooranam- 1gm two times per day with water. 
External Drug      : Nathaichoori ennai for external application. 
 Duration of Drug : 48 days 
 
 40 patients of both genders were recruited for this study. Among the 40 patients, 
22 (55%) patients were females and 18(45%) patients were males. Generally this 
condition is more common in females, this study also concludes the same. 
 Among 40 patients, 17 (42.5%) patients between 36-50 and years, 23 (57.5%) 
patients between 51 and  65 years. Kumbavaatham commonly occurs between the age of 
20-60 years. 
 The majority of patients in this study were Homemakers 18(45%), Cooly 6(15%) 
and  Driver 5 (12.5%).  Businessman 2 (5%), Carpenter 3(7.5%), Clerical 4(10%), 
Baker 1 (2.5%) Electrician 1 (2.5%). 
 The majority of patients in this study were Non vegetarian (95%) remaining          
(5%) patients were vegetarian. 
100% of the patients showed negative family history  
 In this present study, among 40 patients considerable numbers of patients were 
reported from Neithal (30patients) and Marutham (10 patients) 
     All the 40 patients were in pitha kaalam (34-66yrs) 
 Among40 patients 23 patients (57.5%) were affected in durations of 0-3months, 
15(37.5%) patients were affected by the illness from 4-6 months, 2 (5%) were affected 
by the illness from 7-9 months. 
 Out of 40 patients all (100%) had clinical features of pain and restriction of 
movements, radiating pain in affected arm, difficulty in Abduction and External rotation 
and Tenderness was noted in 30 (75%) patients, Local heat was noted in 7(17.5%) 
patients. 
 In this study, Very Good improvement were observed in 10% of cases with 
Varmam and 5% of cases without Varmam  group, Good improvement were observed in 
85% of cases with Varmam and 55% of cases without Varmam,  Moderate improvement 
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observed in 35% of cases without Varmam group and   5% of cases in both the groups 
shows Mild improvement. The result of group A (with Varmam) is significant than 
group B (without Varmam). So the Varmam therapy is beneficial in Kumbavaatham 
patients along with trial medicine. 
 The outcome of this study was clinically observed by SPADI Score, which 
showed encouraging results of very good improvement in 3 patients (7.5%), good 
improvement in 28(70%) patients, moderate improvement in 7 Patients (17.5%)  and 
mild improvement in 2 case (5%).  
 Laboratory investigations were done for all the cases before and after treatment. 
There were no significant variations in hepatic, renal and other parameters before and 
after treatment 
 In this study, no adverse events were observed during the course of the 
treatment. At the time of discharge, all the patients were advised to attend Out-Patient 
Department of Sirappu Maruthuvam of NIS for further follow-up treatment. 
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SUMMARY 
 The disease Kumbavaatham was taken for the clinical study with Rajaelathy 
Chooranam as internal medicine and Nathai choori Ennai as external application. For 
the clinical study, 40 cases were selected based on the approved protocol. 
 This study has been approved by IEC of NIS [Date of IEC Approval & its 
number: NIS/IEC/9-2014-15/15-26.08.2015]. Animal studies were carried out after 
obtaining approval from the Institutional Animal Ethical Committee (IAEC) and the 
trial was registered in Clinical Trial Registry of India (CTRI/2017/05/008593). Hence 
the study is safely executed on patients and there was no adverse drug reactions noted 
during the study period. 
 The toxicological evaluations were conducted as per WHO guidelines for safety 
evaluation of Rajaelathy Chooranam. In short term and long term toxicity study, no 
signs of toxicity and mortality were observed throughout the study period. In organs of 
Control group, no abnormality was detected. The normal histological structure present 
in test group of animals.     
 In clinical trial out of the 40 cases, 20 cases were treated with trial medicine 
along with varmam theraphy, remaining 20 cases were treated with trial medicine only 
in Ayothidoss Pandithar Hospital of National Institute of Siddha, Chennai-47. The 
detailed study on Rajaelathy chooranam with reference to its aetiology, pathogenesis, 
investigations, clinical features, diagnosis and treatment with trial drugs were done.  
 The results were observed by SPADI score. Among the cases treated, 3 
(7.5%)cases had Very Good improvement, 28 (70%)cases had shown Good 
improvement, 7 (17.5%) cases had Moderate improvement and 2 (5%)cases had shown 
Mild improvement. The result of group A (with varmam) is significant than group B 
(without varmam). So the varmam therapy is beneficial in kumbavaatham patients along 
with trial medicine. 
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CONCLUSION 
The present clinical study confirms the efficacy of the trial drugs Rajaelathy 
chooranam (Internally) and Nathai choori Ennai (Externally) with and without Varmam 
therapy. It is also found that the trial medicine along with Varmam therapy shows better 
results when compared with the group B which took the trial medicine only in the 
treatment of Kumbavatham 
The Short term and Long term toxicity studies did not show any toxic effects in the 
animal models. 
 The quantitative outcome of SPADI score shows significant reduction in the 
symptom of Kumbavaatham. There is Very Good improvement was observed in 3 
patients (7.5%), Good improvement was observed in 28 patients (70%), moderate 
improvement in 7 patients (17.5%), and mild improvement in 2 (5%) cases.  
 The result of group A (with varmam) is significant than group B (without 
varmam). So the varmam therapy is beneficial in Kumbavaatham patients along with 
trial medicine. 
 The clinical trial conducted in selected patients was satisfactory and the results 
were encouraging. However a study with large number of patients is required to find out 
the ideal dose response. The cost of the trail medicines is low. These drugs are easily 
available and the dosage is also convenient. These drugs may be taken up for further 
exploratory randomised clinical trials to confirm the efficacy.  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “RAJAELATHY CHOORNAM 
”(INTERNAL ) AND “NATHAICHOORI ENNAI” (EXTERNAL) IN THE TREATMENT OF 
“KUMBAVATHAM ” (PERIARTHRITIS SHOULDER). 
 
Principal Investigator: Dr.C.Shyfa.                                                              
 
FORM I - SCREENING & SELECTION PROFORMA 
 
1. SERIAL NO:      2. OP /IP NO:                 
3. NAME:            4. AGE/GENDER:    
5. OCCUPATION:           6. INCOME:  
 
INCLUSION CRITERIA 
 Age: 20-65        YES\ NO  
 Sex:Both male and female       M \ F 
 Pain and stiffness in shoulder region.     YES\NO    
 Exacerbation of pain on movement     YES\ NO 
 Restricted movements of shoulder joint 
(abduction and external rotation)     YES\ NO 
 With or without pain radiating to upper arm    YES\ NO 
 Patient willingn undergo radiological investigation and give blood samples for 
laboratory investigation       YES\ NO 
 Patient willing to sign the informed consent stating that he/she will consciously 
stick to the treatment but can opt out of the trial of his/her own conscious 
discretion.        YES\ NO 
 
EXCLUSION CRITERIA 
 
 H/O Diabetes Mellitus       YES\ NO 
 H/O Cardiac disease        YES\ NO  
 H/O Septic arthritis       YES\ NO 
 H/O Gonococcal arthritis      YES\ NO                                      
 H/O Pregnancy and lactation      YES\ NO 
 H/O Malignant hypertension      YES\ NO 
 H/O Any fracture or dislocation of shoulder joint    YES\ NO 
 H/O Cervical spondylosis       YES\ NO 
 H/O Any other chronic illness     YES\ NO 
 
ADMITTED TO TRAIL 
YES 
 
NO 
 
If Yes, OPD 
 
IPD 
 
  Serial NO:  
 
Date:        
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                             Signature of the HOD   
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
POST -  GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “RAJAELATY 
CHOORNAM” (INTERNAL) AND “NATHAICHOORI ENNAI” (EXTERNAL) IN 
THE TREATMENT OF   KUMBAVATHAM (Periarthritis Shoulder). 
PRINCIPAL INVESTIGATOR:Dr C. SHYFA 
FORM II – HISTORY TAKING FORM 
 STUDY NO        :    OP / IP NO:    
 NAME:                                                 AGE/GENDER:  
 ADDRESS:                                           CONTACT NO: 
RELIGION:  H / M / C / O          
OCCUPATION:  INCOME: 
MARRITAL STATUS: MARRIED   UNMARRIED         
DATE OF INITIAL ASSESSMENT: 
COMPLAINTS & DURATION: 
PERSONAL HISTORY: 
PERSONAL HABITS YES NO IF YES SPECIFY 
DURATION 
AMOUNT/Qt
y 
             Smoking     
           Tobacco Chewing     
            Alcohol     
          Narcotic  Drug 
Addiction 
    
 
HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN : 
FAMILY HISTORY : 
 Whether this problem runs in family?         1. Yes                              2.No         
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If yes, mention the relationship of affected person(s) 
1._________________     2._________________ 
DIETARY HABIT:   1.Vegetarian                                  2.Non-vegetarian 
 MENSTURAL HISTORY AND OBSTETRIC HISTORY: 
FORM II a 
GENERAL EXAMINATION: 
1. Body weight [Kg]    :                      
2. Height [cms] :                        
3. Body Temperature [0F]       :   
4. Blood Pressure (mm/Hg)  :      
5. Pulse Rate /min. : 
6. Heart Rate / min.  : 
7. Respiratory Rate /min.  :   
Yes            No   
8. Pallor  :   
9. Jaundice  :   
10. Clubbing  : 
11. Cyanosis  : 
12. Pedal Oedema  : 
13. Lymphadenopathy           :  
14. Jugular venous pulsation  :   
 
 VITAL ORGANS EXAMINATION:         Normal          Abnormal 
1.  Heart 
2. Lungs  
3. Brain 
4. Liver 
5. Kidney 
6. Spleen 
7. Stomach   
 
SYSTEMIC EXAMINATION:Normal          Abnormal 
 
1. Cardio-vascular system 
2. Respiratory system         
3. Gastro intestinal system 
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4. Central nervous system 
5. Uro-genital system     
6.  Endocrine system        
 
SIDDHA SYSTEM OF EXAMINATION : 
1. THEGI (TYPE OF BODY CONSTITUTION): 
1. Vaathaudal 3. Kabaudal 
2. Pithaudal4. Thonthaudal 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji 3. Paalai 
2. Mullai4. Neithal 
5. Marutham 
3. KAALAM: 
1. Kaarkaalam4. Pinpanikaalam 
2. Koothirkaalam                                       5. Ilavenilkaalam 
3. Munpanikaalam                                     6. Muthuvenilkaalam 
4. GUNAM: 
1. Sathuvam           2. Rasogunam 
3. Thamogunam 
 
5. PORIPULANGAL (SENSORY ORGANS): 
 1
st
day 8
th
 day 15
th
 
day 
22
nd 
day 
29
th
 
day 
36
th
day 43
rd
day 49
th
day 
Mei (skin)         
Vaai(tongue)         
Kan (eye)         
Mooku(nose)         
Sevi (ear)         
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6. KANMENDRIYAM (MOTOR ORGANS): 
 
7. KOSANGAL (SHEATH):          
 1
st
day 8
th
 day 15
th
day 22
nd
da
y 
29
th
day 36
th
day 43
rd
day 49
th
day 
AnnamayaKosam         
Pranamayakosam         
Manomayakosam         
Vignanamayakosam         
Aananthamayakosam         
 
8.UYIR THATHUKKAL (THREE HUMOURS): 
A. VALI 
 1
st
day 8
th
day 15
th
 day 22
nd
 day 29
th
day 36
th 
day 43
rd
  day 49
th
 day 
Praanan 
        
Abaanan 
        
Viyaanan 
        
 1
st
day 8
th
 day 15
th
day 22
nd
 
day 
29
th
day 36
th
day 43
rd
day 49
th
day 
Kai(upper limb)         
Kaal(lower limb)         
Vaai(speech)         
Eruvai(excretory 
organ) 
        
Karuvai(reproductive 
organs) 
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Udhaanan 
        
Samaanan 
        
Naagan 
        
Koorman 
        
Kirukaran 
        
Devathathan 
        
Dhananjeyan 
        
 
B) AZHAL 
 1
st
day 8
th
 Day
 15
th
 
day 
22
nd
 
day 
29
th
 
day 
36
th
 
day 
 
43
rd
day 
 
49
th
  
day 
Analakam 
        
Prasakam  
        
Ranjakam 
        
Aalosakam 
        
Saathakam 
        
 
C. IYAM:             
 1
st
 day 8
th
 day 15
th
day 22
nd
 
day 
29
th
day 36
th
day 43
rd
day 49
th
 
day 
Avalambagam         
Kilethagam         
Pothagam         
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Tharpagam          
Santhigam          
 
9.SEVEN UDAL DHATHUS: (7 SOMATIC COMPONENTS) 
 
 1
st
day 8
th
day 15
th
day 22
nd
da
y 
29
th
day 36
th 
day 
43
rd
day 49
th
 
day 
Saaram         
Senneer         
Oon         
Kozhuppu         
Enbu         
Moolai         
Sukkilam /         
Suronitham         
 
ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION]  
I. NAADI: [PULSE PERCEPTION] 
 
 
 
 
 
II. SPARISAM: 
1st Day 8
th
 Day 15
th
 
Day 
22
nd 
day 
29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
        
 
1
st
Day 8
th 
day
 
15
th
day 22
nd
day 29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
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III. NAA:[TONGUE] 
1st Day 8
th
 Day 15
th
 
Day 
22
nd 
Day 
29
th
 
Day 
36
th 
Day 
43
rd
 
Day 
49
th
 
Day 
        
 
VI.NIRAM: [COMPLEXION]   
     1. Vaatham                                              3. Kabam 
     2. Pitham 
V.MOZHI: [VOICE] 
1. High Pitched                                     2. Low Pitched 
3. Medium Pitched 
VI.VIZHI: [EYES]  
1st Day 8
th
 Day 15
th
 Day 22
nd 
Day 29
th
 Day 36
th 
Day 43
rd
 Day 49
th
 Day 
        
VII. MALAM: [BOWEL HABITS / STOOLS] 
     Before treatment After treatment 
Niram   
Irugal   
Ilagal   
Others   
 
VIII. MOOTHIRAM [URINE EXAMINATION]   
Neerkkuri Before treatment After treatment 
Niram 
 
  
Manam   
Edai   
Nurai   
Enjal   
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NEIKURI Before treatment After  treatment 
Aravu (Serpentine fashion)   
Aazhi (Annular/Ringed fashion)   
Muthu (Pearl beaded fashion)   
Kalappu (Mixed fashion)   
Other fashion   
 
CLINICAL EXAMINATION:        
 
CLINICAL SYMPTOMS: 
 
AFFECTED SHOULDER : Right                Left                 Both                
 
PAIN AND STIFFNESS 
IN SHOULDER JOINT      :  Mild      Moderate         Severe 
 
ONSET                                :   Sudden                           Gradual 
 
EARLY MORNING STIFFNESS                   :Present or Absent 
 
AGGRAVATING  FACTOR (movements) :  Yes or No 
RELIEVING FACTORS                              : 
TENDERNESS                                              :  
RESTRICTION OF MOVEMENTS           : 
 
CLINICAL EXAMINATION OF SHOULDER JOINT 
I.INSPECTION: 
 
1
st
 
day 
8
th
 
day 
15
th
 
day 
22
nd
day 
29
th
 
day 
36
th
 
day 
43
rd
day 
49
th
 
day 
Attitude:         
Swelling         
Muscle         
wasting 
        
Deformity         
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II.PALPATION: 
 
1
st
 
day 
8
th
 
day 
15
th
 
day 
22
th
 
day 
29
th
 
day 
36
th
 
day 
43
rd
day 
49
th
 
day 
Tenderness         
Local heat         
III. MOVEMENTS of shoulder joint 
 
 1
st
 
day 
8
th
 
day 
15
th
 
day 
22
nd 
day 
29
th
 
day 
36
rd
 
day 
43
rd
 
day 
49
th
 
day 
Flexion          
Extension         
Abduction         
Adduction         
Internal 
rotation 
        
External 
rotation 
        
Shoulder Pain and Disability Index (SPADI)  
Please place a mark on the line that best represents your experience during the last 
week attributable to your shoulder problem.  
PAIN SCALE 
How severe is your pain? 
Circle the number that best describes your pain where: 0 = no pain and 10 = the worst 
pain imaginable 
 
At its worst?  0 1 2 3 4 5 6 7 8 9 10 
When lying on the involved side? 0 1 2 3 4 5 6 7 8 9 10 
Reaching for something on a high shelf? 0 1 2 3 4 5 6 7 8 9 10 
Touching the back of your neck? 0 1 2 3 4 5 6 7 8 9 10 
Pushing with the involved arm? 0 1 2 3 4 5 6 7 8 9 10 
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DISABILITY SCALE : 
How much difficulty do you have?  
Circle the number that best describes your experience where: 0 = no difficulty and 10 = 
so difficult it requires help.  
Washing your hair? 0 1 2 3 4 5 6 7 8 9 10 
Washing your back? 0 1 2 3 4 5 6 7 8 9 10 
Putting on an undershirt or jumper? 0 1 2 3 4 5 6 7 8 9 10 
Putting on a shirt that buttons down the front? 0 1 2 3 4 5 6 7 8 9 10 
Putting on your pants? 0 1 2 3 4 5 6 7 8 9 10 
Placing an object on a high shelf? 0 1 2 3 4 5 6 7 8 9 10 
Carrying a heavy object of 10 pounds (4.5 kilograms) 0 1 2 3 4 5 6 7 8 9 10 
Removing something from your back pocket? 0 1 2 3 4 5 6 7 8 9 10 
 
RESULTS  OF PAIN SCALE : 
 1
st
 day 8
th
 day 15
th
 day 22
nd
 day 29
th
 day 36
th
 day 43
rd
 
day 
49
th
 day 
At its worst?         
When lying on 
the involved 
side? 
        
Reaching for 
some thing on a 
high shelf? 
        
Touching the 
back of your 
neck? 
        
Pushing with the 
involved arm? 
        
Total         
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RESULTS OF DISABILITY SCALE : 
 
 
TOTAL RESULTS 
  
 1
st
 
day 
8
th
 
day 
15
th
 
day 
22
nd
 
day 
29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
Washing your hair? 
        
Washing your back? 
        
Putting on an under 
skirt or a jumper? 
        
Putting on a shirt that 
buttons down the 
front? 
        
Putting on your pants? 
        
Placing an object on a 
high shelf? 
        
Carrying a heavy 
object of 10 pounds (4.5 
kilograms) 
        
Removing something 
from your back pocket? 
        
Total 
        
 1
st
 Day 8
th
 Day 15
th
 
Day 
22
th
 
Day 
29
th
 
Day 
36
th
 
Day 
43
rd
 
Day 
49
th
 
Day 
Total 
Score 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “RAJAELATHI 
CHOORNAM” (INTERNAL) AND “NATHAICHOORI ENNAI” (EXTERNAL) IN THE 
TREATMENT OF   “KUMBAVATHAM” (PERIARTHRITIC SHOULDER) WITH AND 
WITHOUT VARMAM.     
FORM-V–INFORMATION SHEET 
 
Name of Principal Investigator   :Dr .C.Shyfa 
Name of the institute                   : National Institute of Siddha, 
Tambaram Sanatorium, 
Chennai-47. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL: 
I, Dr.C.Shyfa Studying as M.D(Siddha) at National Institute of  Siddha, 
Tambaram Sanatorium is doing a trial on the study of kumbavatham (periarthritic 
shoulder). Periarthritisis a most common persistent joint disease, occurring throughout the 
world. In this regard, I am in a need to ask you few questions. I will maintain 
confidentiality of your comments and data obtained. There will be no risk of disclosing 
your identity and no physical, psychological or professional risk is involved by taking 
part in this study. Taking part in this study is voluntary. No compensation will be paid to 
you for taking part in this study. 
           You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part in 
the study may be of benefit to the community, as it may help us to understand the 
problem of defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
Rajaelathy choornam (Internal medicine) Twice a Day with hot water for 48 days) and 
nathai choori ennai (External medicine) along with varmam therapy for patients who are 
wilin to stay in IPD.Treatment will be provided to you assuring that you will not be 
definitely hurt in any course of treatment. 
 The information I am collecting in this study will remain between you and the 
principal investigator (myself).  
            If you wish to find out more about this study before taking part, you can ask me 
all the questions you want or contact Dr.C.Shyfa, PG Scholar cum principal investigator 
of this study,attached to National Institute of Siddha,Chennai-47. You can also contact 
the Member-secretary of Ethics committee, National Institute Siddha, Chennai 600047,  
for rights and participation in the study. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “RAJAELATHY 
CHOORNAM” (INTERNAL) AND “NATHAICHOORI ENNAI” (EXTERNAL) IN THE 
TREATMENT OF   “KUMBAVATHAM” (PERIARTHRITIC SHOULDER) WITH AND 
WITHOUT VARMAM. 
Name of Principal Investigator: Dr.C.Shyfa    
 
FORM-VI – CONSENT FORM 
 
 
“I have read the foregoing information, or it has been read to me. I have had 
the opportunity to ask questions about it and any questions I have asked have been 
answered to my satisfaction.  
            I consent voluntarily to participate as a participant in this study and understand 
that I have the right to withdraw from the study at any time without in any way it 
affecting my further medical care”. 
 
"I have received a copy of the information sheet/consent form". 
 
Date:  
Signature of the participant 
In case of illiterate participant 
 
        “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
individual has given consent freely.”                                                   
 
 
Date: 
 
 
 
Signature of a witness  
(Selected by the participant bearing no connection with the survey team)   
      
 
 
 
 
 
 
Left thumb Impressionof the Participant 
226 
 
FORM –VI  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG RAJAELATHY 
CHOORNAM (INTERNAL) AND “NATHAICHOORI ENNAI” (EXTERNAL) IN THE 
TREATMENT OF   “KUMBAVATHAM”(PERIARTHRITIC SHOULDER) WITH AND 
WITHOUT VARMAM. 
Name of Principal Investigator: Dr.C.Shyfa     
 
FORM VII -WITHDRAWAL FORM 
 
1. SERIAL NO OF THE CASE:  
2. OP / IP NO:   
3. NAME:   
4. AGE:  
5. GENDER: 
6. DATE OF TRIAL COMMENCEMENT:  
7. DATE OF WITHDRAWAL FROM TRIAL:  
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:               Yes/ No 
Irregular treatment:                           Yes/ No 
Shift of locality:                                     Yes/No 
Increase in severity of symptoms:     Yes/No 
Development of severe adverse drug reactions:   Yes/No 
Development of adverse event:                                             Yes/No 
 
(If YES, give the details of adverse reaction in Form VII -B – Adverse      
Reaction Form / Pharmaco Vigilance Form) 
 
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
COMPARATIVE CLINICAL STUDY OF SIDDHA DRUG “RAJAELATHI CHOORNAM” 
(INTERNAL) AND “NATHAICHOORI ENNAI” (EXTERNAL) IN THE TREATMENT OF 
“KUMBAVATHAM”WITH AND WITHOUT YOGAM. 
Name of Principal Investigator: Dr.C.Shyfa    
 
FORM VII - A – ADVERSE REACTION FORM / PHARMACO VIGILANCE 
FORM 
 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                             AGE:                     GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF THE ADVERSE REACTION OCCUR: 
DESCRIPTION OF ADVERSE REACTION: 
 
 
 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                            Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG 
“RAJAELATHICHOORNAM” (INTERNAL) AND “NATHAICHOORI ENNAI” 
(EXTERNAL) IN THE TREATMENT OF “KUMBAVATHAM” (Periarthritic 
shoulder). 
 
Principal Investigator: Dr.C.Shyfa 
 
1.SERIAL NO:      2. OP /IP NO:                 
3. NAME:            4. AGE/GENDER: 
 
FORM-III - LABORATORY INVESTIGATIONS 
 
BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Hb( gm/dl) 
M:13-18 
W:11-16 
  
T.RBC(millions cells /Cu.mm) 
M:4.5-6.5 
W:3.5-5.5 
  
ESR (mm) 
½ hr. -   
1 hr. 
M:0-10 
W:0-20 
  
T.WBC (Cells /Cu.mm) 4000-11000   
Differential 
Count (%) 
Polymorphs 40-75   
Lymphocytes 20-35   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
 
 
 
 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
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BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Blood 
glucose 
(mg/dl) 
Fasting 70-110   
PP 80-140   
Lipid 
profile 
(mg/dl) 
Serum cholesterol 150-200   
HDL 30-60   
LDL Up to 130   
VLDL 40   
TGL Up to 160   
RFT 
(mg/dl) 
Blood urea 16-50   
Serum creatinine 0.6-1.2   
LFT 
(mg/dl) 
Total bilirubin 0.2-1.2   
Direct bilirubin 0.1-0.2   
Indirect bilirubin 0.2-0.7   
Total protein 6-8   
Serum Albumin 3.5-5.5   
Serum globulin 2-3.5   
SGOT (IU/L) 0-40   
SGPT (IU/L) 0-35   
Alkaline phosphatase 
(IU/L) 
80-290   
 
Serum calcium 9-11   
Serum phosphorus 2-5   
Serum Uric acid 
M:3-9 
W: 2.5-7.5 
  
 CRP   
 ASO titre   
 RA factor   
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B.URINE INVESTIGATIONS: 
 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT 
AFTER 
TREATMENT 
Albumin   
Sugar (Fasting) 
        (PP) 
  
Deposits   
Bile salts   
Bile pigments   
 
 
C.RADIOLOGICAL EXAMINATIONS 
X- Ray: SHOULDER JOINT 
1. Antero posterior  
 
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “RAJAELATHY CHOORNAM” 
(INTERNAL) AND “NATHAICHOORI ENNAI” (EXTERNAL) IN THE TREATMENT OF 
KUMBAVATHAM (PERIARTHRITIC SHOULDER). 
 
Principal Investigator: Dr.C.Shyfa 
 
FORM -VII DIETARY ADVICE FORM 
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